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Zussammenfassung 
 
Die Familie der Transkriptionsfaktoren  Rel/Nuclear factor kappa B (Rel/NF-κB) besteht 
in Säugern aus fünf Mitgliedern: Rel A (p65), RelB, c-Rel, NF-κB1( p105/p50) und NF-
κB2 (p100/p52). Das vom nfκb2 kodierte Protein p100 wird als ein Precursermolekül 
synthetisiert. Durch den proteolytischen Abbau der hemmenden C-terminalen Domäne 
des p100 Precursors kommt es zur Bildung des reifen Proteins p52, welches die Fähigkeit 
besitzt, an DNA zu binden. Durch den induzierten Abbau von p100 über den kürzlich 
beschriebenen alternativen NF-κB Aktivierungsweg kommt es zu einer Translokation des 
p52/RelB-Heterodimers in den Zellkern. Aufgrund dessen fungiert  das p100 als ein 
spezifischer und leistungsfähiger Inhibitor von RelB.  
 
Mäuse, denen spezielle NF-κB-Mitglieder fehlen, zeigen vorwiegend Defekte in der B-
Zell-Aktivierung, weniger in der B-Zell-Entwicklung. In der vorliegenden Arbeit soll die 
Funktion von p100 und RelB im Zusammenhang mit der B-Zell-Entwicklung untersucht 
werden. Hierzu werden p100-/--Mäuse als Modelsystem herangezogen. In den p100-/--
Mäusen, die p52 aber nicht p100 produzieren, wurde eine defekte B-Zell-Entwicklung am 
Beginn der B-Zell-Linien-Entstehung zusammen mit einer fehlerhaften Bildung von B-
Zellen in der marginalen Zone der Milz beobachtet. p100 wird innerhalb der Vorläufer 
von B-Zell-Linien  für die korrekte Entwicklung von reifen B-Zellen benötigt. Wenn das 
p100 als Inhibitor des RelB entfernt wird, dann binden in verschiedenen lymphatischen 
Geweben RelB-Heterodimere konstitutiv an κB-Motive. Die in p100-/--Mäusen 
beobachtete erhöhte DNA-Bindungsaktivität der RelB Hetrerodimere kann auf 
Wildtypniveau zurückgebracht werden, wenn ein Allel des RelB Gens in diesen Mäusen 
inaktiviert wird (p100-/-relB-/+). Dies geht mit einer Erholung der gestörten B-Zell-
Entwicklung einher. Der Rückgang der B-Zell-Entwicklung in p100-/- Mäusen kann auf 
die herabgesetzte Produktion von B-Linien spezifischer Transkriptionsfaktoren (EBF und 
Pax5) zurückgeführt werden, welche ebenso bei p100-/-relB-/+ Mäusen wieder 
angeschaltet werden. Darüber hinaus bestimmt die Funktion des RelB das Schicksal der 
B-Lymphozyten gegenüber den myeloiden Zellen durch eine Induktion der C/EBPα-
Expression. Diese Ergebnisse zeigen die spezifische Rolle des alternativen NF-κB-
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Aktivierungssingnalweges (NF-κB2/p100 und RelB) in Bezug auf die B-Zell-
Entwicklung. Die Aktivität von RelB reguliert die Entwicklung von B220+CD19+ B-
Zellen (Fr. B) im Knochenmark und die Bildung von MZ B-Zellen in der Milz. Die 
gezielte Regulation des p100-Prozessings in den B-Zell-Precursorn ist ein wichtiger 
Vorgang in der Entwicklung der B-Zellen und dient der Unterscheidung  der B-Zell-Linie 
von der myeoloiden Linie. Die Aktivierung von NF-κB durch den Lymphotoxin β 
Rezeptor ist ein kritischer Vorgang in der Entwicklung sekundärer lymphatischer Organe. 
Über die  LTβR-Bindung werden sowohl der klassische (p50/RelA) als auch der 
alternative (p52/RelB) Signalweg  induziert. Um den Einfluss beider Wege auf den NF-
κB-Signalweg downstream des LTβR-Signallings vor allem in Bezug auf die lymphoide 
Organogenese in vivo zu analysieren, wurden Mausmodelle Maus etabliert, in welchen 
spezifisch der relB bzw. der relA Signalweg auf LTβR exprimierenden Zellen inaktiviert 
wurde. Um dies zu erreichen mussten zunächst 3 Mauslinien generiert werden, die ein 
„gefloxtes“ relB (relB flox/flox) oder relA (relAflox/flox) bzw. eine Cre-Rekombinase-Aktivität 
in LTβR-exprimierenden Zellen besitzen. Die Herstellung von relBflox/flox-Mäusen ist 
hilfreich, um die spezifische Funktion von RelB in B-Zellen zu untersuchen, ohne dabei 
die seine Funktion in anderen Zelllinien zu beeinträchtigen. In der vorliegenden Arbeit ist 
die Herstellung der relBflox/flox-Mäuse im Stadium der Keimzell-Übertragung. Es wurden 
insgesamt vier ltbr-cretg Gründer-Linien wurden durch pronucleäre Injektionen von cre-
DNA unter der Regulation eines ltbr Promotors hergestellt. In drei Linien entsprach die 
Expression der cre-mRNA derjenigen der endogenen ltbr-mRNA. Aus diesen wurden 
zwei Gründer Linien ausgewählt, um eine Reportermauslinie (R26R) zur weiteren 
Charakterisierung herzustellen. Des Weiteren wurde ein ltbr-cre-knock-in-targeting-
Vektor pTVFlox-LTβR-Cre konstruiert, der als eine alternative Methode zur 
konventionellen transgenen Anwendungen wie der pronucleären Injektion verwendet 
werden soll.  
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Summary 
 
In mammals, the Rel/NF-κB family of transcription factors consists of five members 
RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2 (p100/p52). p100, encoded by 
the nfκb2 gene, is synthesized as a precursor molecule. The removal of the C-terminal 
inhibitory domain of p100 by proteolytic processing generates mature DNA-binding 
protein p52. Degradation of p100 via the recently discovered alternative NF-κB 
activation pathway results in nuclear translocation of p52/RelB heterodimers.  
 
Mice lacking individual NF-κB members manifest defects mainly in B-cell activation 
rather than in B-cell development. The major goal of first project is to understand 
whether NF-κB2/p100 and RelB function in B-cell development by using p100-/- mice as 
a model system. Not only an arrested mainstream B-cell development at the onset of B-
lineage commitment, but also an impaired marginal zone B-cell generation, was found in 
p100-/- mice (still producing p52 but not p100) in a cell-intrinsic manner. RelB complex 
bound constitutively to κB motifs in various lymphoid tissues when p100, the inhibitor of 
RelB, was deleted. The elevated RelB DNA-binding activity was restored to wild-type 
levels when one allele of the relB gene was deleted in p100-/- mice (p100-/-relB-/+ mice), 
correlated with the rescued B-cell development. The impaired B-cell development in 
p100-/- mice was likely due to the reduced expression of B-lineage transcription factors 
EBF and Pax5, which was also rescued in p100-/-relB-/+ mice. Moreover, the increased 
RelB function determined the fate of B lymphocytes versus myeloid cells, likely due to 
the contribution of enhanced C/EBPα expression in p100-/- B-cell precursors. Thus, the 
findings here unravel a specific role of alternative NF-κB activation pathway (NF-
κB2/p100 and RelB) with respect to B-lymphocyte development. RelB activity regulates 
the emergence of B220+CD19+ B cells (Fr. B) in bone marrow and the generation of MZ 
B cells in spleen. The tightly controlled p100 processing in B-lineage precursors is an 
important event in B-cell development and B-lymphoid/myeloid-lineage decision.  
 
The activation of NF-κB through lymphotoxin β receptor (LTβR) is critical for secondary 
lymphoid organogenesis. LTβR signaling induces both classical (p50/RelA) and 
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alternative (p52/RelB) complexes. To in vivo dissect the individual contribution of each 
NF-κB activation pathway downstream of LTβR signaling with a specific focus on the 
secondary lymphoid organogenesis, one approach is to generate mouse models, in which 
relB or relA can be selectively inactivated in LTβR-expressing cells. Towards this goal, 
three mouse strains need to be established, including mice harboring floxed relB 
(relBflox/flox) or relA alleles (relAflox/flox, generated) and mouse strain with Cre recombinase 
activity in LTβR-expressing cells. The generation of relBflox/flox mice is expected to be 
helpful to characterize specific function of RelB in B cells without losing its function in 
other lineages. In this study, the generation of relBflox/flox mice is in the stage of germline 
transmission. Four ltbr-cretg founder lines were generated by pronucleus injection of cre 
cDNA under the control of the ltbr gene promoter. In three founder lines, the tissue 
expression pattern of cre mRNA was consistent with that of endogenous ltbr mRNA. 
Two lines were selected to breed with a reporter mouse line (R26R) for further 
characterization. The targeting vector pTVFlox-LTβR-Cre, leading to the generation of 
ltbr-cre knock-in mice as an alternative method to the conventional transgenic approach 
by pronucleus injection, was also constructed.  
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1  INTRODUCTION 
Rel/nuclear factor (NF)-κB is a dimeric transcription factor comprised of 50 kDa and 65 
kDa subunits. It was originally identified as a constitutive nuclear B-cell-specific protein 
that binds to κB regulatory motifs within the intronic enhancer of the immunoglobulin Cκ 
light chain gene. As its binding activity was closely associated with expression of the Cκ 
gene, it was showed to be involved in B-cell maturation. It is now clear that this DNA-
binding activity is the result of multiple Rel/NF-κB related dimers and that these 
transcription factors are present in all cells [1]. 
 
1.1  NF-κB signaling pathway 
The Rel/NF-κB family of transcription factors plays a pivotal role in diverse biological 
processes including innate and adaptive immune responses, inflammation, cell growth 
and differentiation, apoptosis and survival, cancer, and lymphoid organogenesis. 
 
1.1.1   Rel/NF-κB family of transcription factors 
The Rel/NF-κB proteins belong to two classes in vertebrates: one consisting of RelA 
(p65), RelB, and c-Rel, proteins that are synthesized in their mature forms. These proteins 
share a highly conserved N-terminal 300 amino acids long Rel-homology domain (RHD). 
The RHD contains a nuclear localization sequence (NLS) and is involved in dimerization, 
sequence-specific DNA binding, and interaction with the inhibitory IκB proteins. The 
second class consists of NF-κB1 (p105/p50) and NF-κB2 (p100/p52), which are 
synthesized as precursor molecules (p105 and p100) with N-terminal RHD and C-
terminal ankyrin repeats (Figure 1.1 A). Ubiquitin-dependent proteolysis removes the C-
terminal domain, resulting in the production of mature DNA-binding proteins (p50 and 
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p52). p50 and p52 lack transactivation domain (TAD) that is present in the C-terminal of 
RelA, RelB, and c-Rel. The NF-κB proteins form numerous homo- and heterodimers [2, 
3]. RelB is unique in that it does not homodimerize, and further, is unable to 
heterodimerize with c-Rel or p65. It forms heterodimers with p100, p52, and p50 [4, 5]. 
NF-κB dimers bind to the consensus sequences GGGRNNYYCC, where R is purine, Y is 
pyrimidine, and N is any base. 
 
 
Figure 1.1: Schematic representation of Rel/NF-κB, IκB, and IKK families. Members of the 
Rel/NF-κB, IκB, and IKK families are shown. The number of amino acids in each protein is 
indicated in the right. Presumed sites of cleavage for p100 (amino acid 447) and p105 (amino acid 
433) are shown. Phosphorylation (S) and ubiquitination (K) sites on p100, p105, and IκB proteins 
are indicated. RHD: Rel homology domain; TAD: transactivation domain; LZ: leucine zipper 
domain on IKK and RelB; GRR: glycine-rich region; HLH: helix–loop–helix domain; Z: zinc 
finger domain; CC1/2: coiled-coil domains; NBD: NEMO-binding domain; α: α-helical domain. 
(Adapted from [6])  
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1.1.2  IκB family members 
In most cell types, NF-κB dimers are retained in the cytoplasm by IκB. The IκB family, 
which includes IκBα, IκBβ, IκBε, IκBγ, and Bcl-3 in mammalian cells, is characterized 
by the presence of multiple ankyrin repeats that mediate binding to the RHD of NF-κB 
proteins (Figure 1.1 B). The ankyrin repeats are also present in the C-terminal halves of 
NF-κB2/p100 and NF-κB1/p105 precursors, which function like IκB molecules. Binding 
to IκB prevents the NF-κB complex from translocation to the nucleus, thereby 
maintaining NF-κB in an inactive state. Although there is a possible functional 
redundancy among the IκB proteins, their different affinity to each NF-κB dimer, the 
number in the ankyrin repeats, and the expression pattern determine the specificity in the 
regulation of NF-κB activity by individual IκB protein. For instance, IκBα, IκBβ, and 
IκBε are shown to preferentially bind to RelA or c-Rel. In contrast, Bcl-3 binds to p50 or 
p52 homodimers and NF-κB2/p100 binds to RelB. 
 
1.1.3  IκB kinase (IKK) complex 
Degradation of IκB proteins is a tightly regulated process that is initiated upon 
phosphorylation by activated IκB kinase (IKK). IKK is a complex composed of three 
subunits: IKKα or IKK1 (85 kDa), IKKβ or IKK2 (87 kDa), and IKKγ or NEMO/IKKAP 
(48 kDa) [7]. IKKα and IKKβ are highly homologous proteins with 52% sequence 
identity. They contain N-terminal kinase domains as well as leucine zipper (LZ) and 
helix-loop-helix (HLH) motifs (Figure 1.1 C). They can form homo- or heterodimers by 
virtue of the LZ motifs and the dimerization is essential for the kinase activity. The third 
subunit IKKγ is the regulatory subunit [8]. IKKγ lacks a kinase domain and exists as a 
dimer or trimer. Gel filtration analysis indicates that the IKK complex is a large complex, 
700–900 kDa in size, suggesting the presence of additional components. Recently, Cdc37 
and Hsp90 have been suggested to serve as additional components of the IKK complex 
[9]. A large number of protein kinases including different protein kinase C (PKC) 
isozymes and the mitogen-activated protein kinase kinase kinase (MAPKKK) family 
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members such as NF-κB-inducing kinase (NIK), AKT/PKB, MEKK1, MEKK2, and 
MEKK3 are found to be inducible activators of the IKK complex [10, 11].  
 
1.1.4  NF-κB activation pathway  
Two major signaling pathways lead to the translocation of NF-κB dimers from the 
cytoplasm to the nucleus. Potent activators, such as tumor necrosis factor (TNF), 
interleukin-1 (IL-1), and lipopolysaccharide (LPS) activate the IKK complex. In the 
classical NF-κB signaling pathway (Figure 1.2, right part), the activated IKK complex 
(predominantly in an IKKβ and IKKγ dependent manner) catalyzes the phosphorylation 
of IκB protein (at sites equivalent to Ser32 and Ser36 of IκBα), polyubiquitination (at 
sites equivalent to Lys21 and Lys22 of IκBα), and subsequent rapid degradation by the 
26S proteasome. The released NF-κB dimers (mainly p50/RelA heterodimers) translocate 
to the nucleus, bind DNA, and activate the transcription of κB target genes. 
 
Recently, an alternative pathway for NF-κB activation that is dependent on NIK and 
IKKα has been identified (Figure 1.2, left part). This pathway is independent of IKKβ 
and IKKγ [12-15]. The substrate of NIK-IKKα in this pathway is NF-κB2/p100, which 
can be phosphorylated at two C-terminal serine residues. Phosphorylation of these sites is 
essential for p100 processing to p52, which further undergoes polyubiquitination and 
proteasomal degradation. However, instead of complete p100 degradation, as seen in IκB 
proteins, phosphorylation-dependent ubiquitination of p100 merely results in the 
degradation of its inhibitory C-terminal half of p100. Once the C-terminal half is 
degraded, the N-terminal portion of p100, p52 containing the RHD, is released. As the 
RHD of p100 is most commonly associated with RelB, activation of the alternative 
pathway predominantly results in nuclear translocation of p52/RelB heterodimers. Thus, 
p100 functions as a specific and potent inhibitor of RelB. This alternative pathway can 
also be induced by activation of lymphotoxin β receptor (LTβR), B-cell activating factor 
belonging to the TNF family receptor (BAFF-R), CD40, and LPS but not TNFR1/TNFR2 
[16-19]. 
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Figure 1.2: Activation of NF-κB by the alternative (left) and the classical (right) pathways. 
Signalings through TNFR, IL-1R, and TLR activate the classical NF-κB pathway involving 
predominantly the β and γ subunits of the IKK complex. Nuclear translocation and DNA-binding 
of p50/RelA heterodimers are accomplished through IκBα phosphorylation and ubiquitin-
dependent proteasomal degradation. Membrane-bound LTα1β2 heterodimers, CD40L, and BAFF, 
on the other hand, activate via NIK and IKKα. Phosphorylation of p100 results in the processing 
of the precursor of the p52 subunit and nuclear accumulation of p52/RelB heterodimers. There is 
significant cross talk, since signaling through the LTβR also results in the induction of RelA 
complexes and LPS can also trigger the processing of p100 to p52. It is likely that the two 
pathways activate distinct or only partially overlapping sets of genes. (Adapted from [13]) 
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1.1.5  Distinct and redundant functions of NF-κB proteins 
Rel/NF-κB family members have distinct as well as redundant functions, which are 
indicated by the phenotypes observed in mice lack for individual NF-κB proteins. The 
pathological changes and cell lineages affected in different NF-κB mutant mice are listed 
in Table 1-1 [20]. 
 
NF-κB 
deficient mice Phenotypes 
nfκb1-/- 
Develop normally and exhibit no histopathological changes [21]; 
exhibit multiple defects in the function of immune system; susceptible 
to Listeria monocytogenes and Streptococcus pneumoniae, respond 
normally to Haemophilus influenza and Escherichia coli, and more 
resistant to murine encephalomyocarditis (EMC) virus due to the 
increased production of β-interferon [21] 
nfκb2-/- 
Develop normally; absence of marginal zone in spleen; disorganized 
B- and T-cell areas in spleen and lymph nodes; lack of Peyer’s 
patches; fail to mount a T-cell dependent antibody response [22, 23] 
relA-/- 
Embryonic lethality between days E15 and E16 postcoitum due to 
fetal hepatocyte apoptosis; relA-/- fibroblasts and macrophages also 
exhibit increased sensitivity to apoptosis induced by TNFα [24] 
relB-/- 
Multi-organ inflammation; atrophy of thymic medulla; splenomegaly; 
disorganized B- and T-cell areas in spleen; myeloid hyperplasia in 
spleen and bone marrow; absence of lymph nodes and Peyer’s patches 
[25-27] 
c-rel-/- 
Develop normally; defects in B-cell proliferation and isotype 
switching [28, 29]; c-rel-/- T cells fail to proliferate in response to 
mitogens which can be overcome by exogenous IL-2; activated T cells 
also express reduced amounts of IL-3 and GM-CSF [29, 30] 
Table 1-1: Pathological changes in mice deficient in individual Rel/NF-κB proteins. 
Lack of both nfκb1 and nfκb2 in mice results in osteopetrosis, B-cell developmental 
defects, thymic and lymph node atrophy, disorganized spleen structure, and myeloid 
hyperplasia [31]. tnfr-/-relA-/- mice can survive embryonic lethality. They lack lymph 
nodes as well as Peyer’s patches and reveal defective spleen architecture [32]. relA-/-c-rel-
/- mice die between days E15 and E16 postcoitum as a result of fetal hepatocytes 
apoptosis [33]. nfκb1-/-relA-/- mice, like relA-/-c-rel-/- mice, display an earlier onset of 
embryonic death (around E13) due to fetal liver apoptosis [34]. nfκb1-/-relB-/- mice reveal 
increased severity that is observed in relB-/- mice [13, 35]. 
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1.1.5.1  Mice lack of C-terminal inhibitory domain of p100  
NF-κB2 is synthesized as precursor molecule p100. The removal of C-terminal inhibitory 
domain of p100 precursor by proteolytic processing generates active p52. To better 
understand the physiological roles of NF-κB2, particularly the p100 precursor in vivo, 
p100-/- mice have been generated by Rodrigo’s lab [36]. In these mice, targeted disruption 
of the C-terminal portion of the nfκb2 gene is generated by introducing a stop signal at 
codon 451 in combination with a SV40 poly (A) and the neo cassette, which results in the 
expression of 450 amino acids long p52 molecule, rather than the full-length p100 
precursor (Figure 1.3).  
 
Figure 1.3: Schematic representation of the targeting strategy of C-terminal ankyrin 
repeats domain in the nfκb2 gene. In p100-/- mice, the targeted disruption of the C-terminal 
portion of the nfκb2 gene is generated by introducing a stop signal at codon 451 followed by 
SV40 poly (A) and the neo cassette. 
 
p100-/- mice appear normal at birth but develop multiple pathologies postnatal. These 
pathologies include gastric hyperplasia, spleen and thymic atrophy, enlarged lymph 
nodes, and myeloid hyperplasia. p100-/- mice survive no longer than 21 days after birth 
mainly due to the marked gastric hyperplasia. A significant increase of κB DNA-binding 
activity, mainly comprising RelB complexes, is found in different lymphoid and non-
lymphoid tissues of p100-/- mice. The expression of Rel/NF-κB-regulated genes such as 
TNFα, ICAM1, and VCAM-1 is upregulated in p100-/- mice.  
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1.2  B-lymphocyte development 
B cells are an important component of adaptive immunity. The main function of B-cell is 
to produce and secrete soluble antibodies that recognize foreign antigens (bacterial, 
fungal, etc.). These Y-shaped antibodies, of which there are five classes (IgM, IgD, IgG, 
IgA, and IgE), are composed of two heavy chains and two light chains. 
 
B cells develop in bone marrow, liver (in the fetus), and a specialized organ termed the 
bursa of Fabricius in birds. B-cell takes its name from ‘bursa’. B-cell development is a 
tightly controlled process. Generation of immature B cells in bone marrow is referred to 
as central (or primary) B-cell development. Bone marrow B-lineage precursors proliferate 
and progress through a highly regulated maturation process that culminates in the 
production of immature, surface immunoglobulin (Ig)-expressing B lymphocytes. These 
newly formed, immature B-lymphocytes then migrate into spleen, where they 
differentiate into mature, naïve B cells in a process referred to as peripheral (or 
secondary) B-cell development (Figure 1.4).  
 
The number of B-lineage cells in bone marrow is far greater than the number of mature B 
cells that are generated in spleen [37, 38]. The marked cell loss, occurring during the 
process of generating bone marrow B-lineage, is due to a series of selection events. First, 
Ig heavy-chain gene rearrangements are productive in only approximately one third of 
pro-B cells. Furthermore, an even smaller fraction of these cells progress to complete 
functional light-chain gene rearrangements [39]. Those cells with nonproductive Ig gene 
rearrangements undergo apoptosis and are eliminated from bone marrow, possibly by a 
macrophage mediated mechanism [40]. Finally, selection events are also operative in 
cells that have differentiated to the surface IgM+ stage. Some of these surface IgM+ cells 
are eliminated, because they are potentially self-reactive [41, 42]. As a result, while 
approximately 2 × 107 IgM+ immature bone marrow B lymphocytes are produced daily in 
mouse, only 5-10% of these cells survive and exit bone marrow as transitional B cells 
[43-45]. 
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Immature splenic B cells are referred to as ‘transitional’ cells because they are ‘in transit’ 
from bone marrow and they comprise a distinct short-lived ‘developmental transition’ 
from immature into mature B cells. Transitional B cells comprise approximately 10-15% 
of all splenic cells. There are at least two major subsets of transitional B cells, transitional 
type 1 (T1) and type 2 (T2) (Figure 1.4) [46]. As for the mature B cells in spleen, there 
are three main types: follicular mature (FO), marginal zone (MZ), and B 1 cells [47]. B1 
B cells, which are enriched in peritoneal and pleural cavities, are self-renewing cells [48]. 
 
Figure 1.4: An overview of B-cell development in bone marrow and spleen. In bone marrow, 
common lymphoid progenitors (CLPs) commit to B-cell lineage through pro-B and pre-B stages. 
Immature B cells, which have rearranged their immunoglobulin genes, subsequently migrate to 
spleen and differentiate to mature FO and MZ B cells. T1: transitional type 1, T2: transitional 
type 2. 
 
1.2.1       Transcriptional control of early B-cell development  
The development of B-lineage cells from multipotent progenitors requires the 
coordinated activity of many transcription factors. These proteins have been shown to 
function in a transcriptional hierarchy, and in a combinatorial manner, to regulate the 
expression of genes that comprise the B-lineage differentiation program. PU.1, E2A, 
early B cell factor (EBF), and B-cell-specific activator protein (BSAP)/Pax5 are critical 
for the proper development of early B-lymphoid cells. 
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1.2.1.1  Early B-cell development process 
The hematopoietic system continuously regenerates all blood cells throughout life. One 
of the earliest steps is the commitment of pluripotent progenitors to either common 
lymphoid progenitors (CLPs) or common myeloid progenitors (CMPs). The IL-7 receptor 
(IL-7R)+ CLPs give rise to all lymphocytes (B, T, DC, and NK cells) whereas the IL-7R- 
CMPs are able to generate all myeloid cell types (erythrocytes, megakaryocytes, 
granulocytes, and macrophages) [49].  
 
Subsequent expression of the pan B-cell marker B220 on CLPs coincides with the 
differentiation to pre-pro-B cells. Cells at pre-pro-B stage, also termed as Fraction (Fr.) 
A1/A2 according to the nomenclature of Hardy, are B220+CD43+CD19-IgM- [50]. The 
early pro-B (termed as Fr. B) cells represent committed B-lineage cells that have 
undergone rearrangement of DH-JH segments at immunoglobulin heavy chain locus 
(Figure 1.5) [51]. Productive VH-DJH recombination at late pro-B stage (Fr. C) results in 
the expression of Igµ proteins as part of pre-B cell receptor (pre-BCR) on the cell surface. 
The transition from pre-pro B stage (Fr. A) to early pro-B stage (Fr. B) is characterized 
by the expression of CD19 [52, 53]. The acquisition of CD19 expression actually 
represents an important step in murine B-lineage differentiation and corresponds to the 
ability of pro-B cells to proliferate in response to IL-7 without other stromal cell derived 
factors [50, 51]. The pre-BCR acts as an important checkpoint to control the transition 
from pro-B to pre-B stage. At the pre-B stage, the heavy chain is associated with a 
surrogate light chain, λ5 and VpreB, as well as the signal transducing molecules mb1/Igα 
(CD79α) and B29/Igβ (CD79β). Signaling through pre-BCR promotes allelic exclusion at 
the IgH locus, stimulates proliferate cell expansion, and induces differentiation to small 
pre-B cells, which start to recombine immunoglobulin light-chain genes. Successful light-
chain gene rearrangement leads to the emergence of immature IgM+ B cells that emigrate 
from bone marrow to the periphery [54, 55]. 
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Figure 1.5: Schematic diagram of B-cell development in bone barrow. The expression of 
signaling receptors, the rearrangement status of immunoglobulin genes, and the initiation of 
expression of characteristic cell surface proteins are indicated for successive progenitor cell 
stages in mouse B lymphopoiesis. Lin-, negative for the expression of lineage-specific markers. 
(Adapted from [56]) 
 
1.2.1.2  PU.1 
PU.1 (Spi-1) is a member of the Ets transcription factor family that is expressed 
exclusively in hematopoietic cells [57]. PU.1 plays an essential role in the development 
of both lymphoid and myeloid lineages [57, 58]. PU.1 expression is highest in 
macrophages but can also be detected in neutrophils, B, and early T lymphocytes. PU.1-/- 
mice die around birth and fail to generate myeloid as well as lymphoid cells, but do 
contain normal erythrocytes and megakaryocytes [58, 59]. The PU.1-/- progenitor cells 
propagate in vitro in the presence of the multilineage cytokines IL-3, IL-6, and SCF, but 
fail to respond to M-CSF, G-CSF, GM-CSF, and IL-7 owing to the absence or the 
reduced expression of the corresponding receptors [60]. Retroviral reconstitution 
experiments have implicated a role of PU.1 in the myeloid versus lymphoid lineage 
decision, as low PU.1 expression induces B-cell development in PU.1-/- progenitors, 
whereas high PU.1 level suppresses the B-cell fate and promotes instead macrophage 
differentiation [61, 62]. PU.1 has been implicated in the regulation of expression of IL-
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7Rα, which is required for proper lymphoid development, and M-CSF, which is required 
for proper macrophage development. 
 
1.2.1.3  E2A 
The E2A gene encodes two proteins E12 and E47, which are members of the basic helix–
loop–helix (bHLH) family of transcription factor [63]. E2A proteins belong to a subgroup 
of bHLH proteins, referred to as E-proteins that also includes HEB and E2-2 [64]. These 
E-proteins bind to a common ‘E-box’ motif, 5’-CANNTG-3’, and form homo- and 
heterodimers with other bHLH proteins. E12 and E47 are expressed in many cell types in 
a heterodimeric form but form a unique homodimeric complex only in B-lineage cells 
[65, 66]. Most E2A-/- mice die before or shortly after birth [67, 68]. B-cell development in 
E2A-/- mice is arrested at the earliest stage in the absence of DH-JH rearrangements (pre-
pro-B stage). The few B220+CD43+ cells in E2A-/- bone marrow express IL-7R, Igβ/B29, 
and Igµ transcripts, whereas Rag1, mb-1, λ5, CD19, and Pax5 expression could not be 
detected [68, 69]. Interestingly, transgenic expression of either E12 or E47 is sufficient to 
promote the development of B-lineage cells, indicating functional redundancy between  
these two proteins with respect to their roles in B-cell development [65]. 
 
1.2.1.4  EBF 
EBF belongs to the transcriptional regulatory protein family O/E proteins, which are 
expressed in olfactory neurons, adipocytes, and B lymphocytes. EBF binds the 
palindromic sequences 5’-ATTCCCNNGGGAAT-3’ through an N-terminal cysteine-rich 
DNA-binding domain containing a zinc coordination motif [55, 70, 71]. EBF is expressed 
at all stages of B-lineage differentiation with the exception of terminally differentiated 
plasma cells [72, 73]. Interestingly, the lack of EBF arrests B-cell development at the 
same stage as observed in E2A-/- mice [74]. The few B220+CD43+ cells present in EBF-/- 
bone marrow express IL-7R as well as Igµ transcripts, but fail to transcribe Rag1, Rag2, 
mb-1, Igβ/B29, λ5, VpreB, CD19, and Pax5 genes [74]. 
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The similar defects in B-cell development of E2A and EBF mutant mice strongly 
suggests that these two transcription factors act in concert to control the earliest phase of 
B lymphopoiesis. EBF is a likely the target of E2A [68, 74, 75]. Compound heterozygous 
E2A+/-EBF+/- mice provide direct genetic evidence for this cooperation, because B-cell 
development is arrested at a slightly later stage (early pro-B stage) than that caused by 
deletion of either gene [76]. Forced expression of E2A and EBF in hematopoietic 
precursors reveals that they do cooperatively activate many B-cell-specific genes [77, 
78]. Hence, an important function of E2A and EBF is to activate the B-lymphoid gene 
expression program at the onset of B-cell development [76]. However, the mere 
activation of B-cell-specific gene expression program and VH-JH recombination by E2A 
and EBF is not sufficient to commit B-cell progenitors to B-lymphoid lineage in the 
absence of Pax5 [79]. 
 
1.2.1.5  Pax5 
B-cell-specific activator protein (BSAP) is encoded by the Pax5 gene and is expressed in 
all B-lineage cells with the exception of plasma cells. In Pax5-/- mice B-cell development 
is arrested at the early pro-B-cell stage, resulting in the lack of CD19+ cells in bone 
marrow. B-lineage progenitors are able to rearrange DH-JH but no detectable VH-DJH 
rearrangements [79-81]. Pax5-/- pro-B cells express E2A and EBF at normal levels, 
indicating that E2A and EBF are upstream of Pax5 in the genetic hierarchy of B-cell 
development. In addition, most B-lineage-associated genes are expressed normally with 
the exception of CD19, N-myc, mb-1, and LEF-1, which have been shown to be Pax5 
target genes [82]. 
 
Pax5-/- pro-B cells, which can be cultured ex vivo in the presence of IL-7 and stromal 
cells, still retain a broad lympho-myeloid potential characteristic of uncommitted 
progenitors [83, 84]. Upon IL-7 withdrawal and appropriate cytokine stimulation, Pax5-/- 
pro-B cells are able to differentiate in vitro into functional T cells, NK cells, dendritic 
cells, macrophages, osteoclasts, and granulocytes (Figure 1.6) [83]. This multilineage 
potential of Pax5-/- pro-B cells is, however, suppressed by retroviral restoration of Pax5 
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expression, which rescues the development to the mature B-cell stage [82]. Following 
injection into Rag2-/- mice, Pax5-/- pro-B cells are able to home to bone marrow, where 
they undergo self-renewal and develop into functional cells of all major hematopoietic 
lineages including T cells and erythrocytes [84, 85].  
 
Figure 1.6: B-lineage commitment by Pax5. Pax5-/- pro-B cells are early progenitor cells, 
which can differentiate along the indicated hematopoietic lineages with the exception of B-cell 
pathway. (Adapted from [56]) 
 
Interestingly, the ectopic expression of C/EBPα and GATA transcription factors strongly 
promotes myeloid differentiation of Pax5-/- pro-B cells in vitro [86]. C/EBPα is a member 
of CCAAT/enhancer-binding protein family, which contains a conserved leucine-zipper 
dimerization motif adjacent to a basic DNA-binding domain [87]. Within the 
hematopoietic system, C/EBPα is exclusively expressed in early myeloid progenitors. It 
is upregulated during granulocyte development and downregulated along the monocytic 
pathway [88, 89]. The loss of C/EBPα in mice results in the complete absence of mature 
granulocytes due to the arrest at an early myeloblast stage [90]. Recently, it was shown 
that the enforced expression of C/EBPα or C/EBPβ in differentiated B cells leads to a 
rapid and efficient reprogramming into macrophages. C/EBPs induce these process by 
inhibiting Pax5, leading to the downregulation of its target gene CD19, and synergizing 
with endogenous PU.1, resulting in the upregulation of its target Mac-1 [91].  C/EBPβ 
may also play a role in B-cell differentiation since ablation of this factor, which is 
expressed predominantly in mature B cells [92], leads to a decreased number of B cells in 
bone marrow. 
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At lineage commitment, Pax5 fulfills a dual role by repressing the ‘lineage-inappropriate’ 
genes and simultaneously activating the B-cell-specific genes, which leads to the 
consolidation of B-lymphoid gene expression program [83]. The M-CSFR and BLNK 
genes are illustrative examples of both classes of genes. The expression of M-CSFR 
enables Pax5-/- pro-B cells to differentiate into monocytes under the influence of M-CSF, 
whereas its repression by Pax5 renders B-cell precursors unresponsive to this myeloid 
cytokine. On the other hand, the BLNK gene is entirely dependent on Pax5 function for its 
expression in committed B-lymphocytes (Figure 1.7) [81, 93]. 
 
 
Figure 1.7: Dual role of transcription factor Pax-5 in B-cell development. Pax-5 inactivates 
myeloid signaling by repressing the M-CSFR gene. It also represses myeloperoxidase (MPO) 
expression. At the same time, Pax-5 activates (pre)-BCR signaling by promoting VH-DJH 
rearrangements and by inducing the expression of BLNK, CD19, and mb-1. (Adapted from [56]) 
 
1.2.2  Spleen marginal zone and marginal zone B cells 
The splenic marginal zone (MZ) is the major route of entry of antigens, antigen 
presenting cells, and lymphocytes into the white pulp [13]. It is located at the outer limit 
of the white pulp (WP), bordered innermost by the MZ sinus and outermost by the red 
pulp (RP). The marginal sinus surrounds B-cell follicles and T-cell areas (periarteriolar 
lymphoid sheath; PALS) (Figure 1.8) [48, 94]. The MZ is characterized by the presence 
of two distinct macrophage populations MZ macrophages (MZM) and metallophilic 
marginal macrophages (MMM), separating red and white pulp in spleen. These 
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specialized macrophages can be discriminated by ER-TR9 and MOMA-1 mAbs, 
respectively. The mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) is 
expressed on stromal sinus-lining cells in the MZ. 
 
The main compartment of MZ-resident lymphocytes comprises ‘naïve’ MZ B cells, 
which have a distinctive phenotype and function compared to mainstream B cells. MZ B 
cells only represent about 5% of splenic B cells. MZ B cells is characterized by high 
surface expression of CD21/CD35 and negative/low expression of CD23, whereas 
follicular B cells are CD21/CD35inCD23in [13]. The β2, LFA-1, and α4β1 integrin are 
expressed at higher levels on MZ B cells compared to follicular B cells [95]. It has been 
shown that the ‘naïve’ MZ B-cell compartment originates from recirculating precursors 
from rat lymph [96]. The MZ and MZ B-cell compartment are not fully formed until 3-4 
weeks after birth in rodents and 1-2 years in humans. The precise cellular and molecular 
basis for the delay in MZ B cell maturation remains unclear, but this delay may have a 
clinical correlation in the inability of infants under the age of two to mount effective 
immune responses to selected polysaccharide antigens [48].  
 
MZ B cells are a crucial component of early immune responses to blood-borne pathogens 
[94]. Along with B1 B cells, they have been described as cells that are endowed with 
“natural memory” and that provide a bridge between innate and adaptive immune 
responses. These two types of B cells are believed to be the source of most natural 
antibodies. MZ B cells also play an important role in the immune response to T-
independent type 2 (TI-2) antigens. Pyk-2-deficient mice lack MZ B cells. These mice 
have a striking defect in TI-2 responses to artificial multivalent antigens [97]. Mice that 
lack NF-κB1 have a defect in MZ B-cell development, and these mice are defective in 
their ability to defense a number of gram-negative bacteria [98]. 
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Figure 1.8: Microstructure of spleen and spleen marginal zone. Central arterioles are 
surrounded concentrically by PALS and B-cell follicles. These arterioles branch into follicular 
arterioles, which feed into the marginal sinus. The marginal zone lies between the sinus and the 
red pulp of spleen. Inset shows the marginal zone in cross-section. MZ B cells play pivotal roles 
in cooperation with MZ macrophages and dendritic cells in filtering mechanism of spleen to clear 
blood-borne antigens. FA: follicular arteriole; RC: reticular cell. (Adapted from [99]) 
 
1.2.2.1  Molecular signals that affect marginal zone B cells 
The origin of MZ B cells is not well defined. The current model for the cellular pathway 
in generating of MZ B cells is shown in Figure 1.4. The detailed molecular nature of 
signaling that is required for MZ B-cell generation and maintenance, as well as the 
intercellular signals between resident MZ cells is not clear. Many recent studies using 
mutant mouse models underscore clearly the direct or indirect involvement of several 
signaling pathways. They are summarized in Table 1-2.  
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Table 1-2: Knockout and transgenic mice with alterations in MZ B cells. Mouse models have 
been classified into the following groups: signals that involve the BCR, pathways that involve in 
the lifespan and survival of MZ B cells, and signals that participate in MZ B-cell retention and 
migration. (Adapted from [48]) 
 
1.2.3  Rel/NF-κB function in B-cell maturation and activation 
The expression and intranuclear level of Rel/NF-κB subunits change substantially during 
B-cell maturation, indicating that these proteins play a critical role in B lymphopoiesis. c-
Rel is expressed at all stages of B-cell development, but is expressed at the highest level 
and is constitutively nuclear in mature B cells [100]. RelB is expressed during the later 
stages of B-cell maturation and can bind to regulatory sites within the Ig heavy chain 
locus. Terminally differentiated plasma cells and LPS-differentiated B cells express all 
five isoforms (p52, RelB, c-Rel, p50, and RelA). The nuclear κB DNA-binding activity in 
mature B-lymphocytes consists mainly p50/c-Rel heterodimers, which is different from 
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pre-B cells that have largely inducible p50/p65 heterodimers [101] . Despite changes in 
the abundance and the subunit composition of NF-κB transcription factors throughout B-
cell development [102, 103], mice lacking individual NF-κB protein have defects mainly 
in B-cell activation rather than development (Table 1-3). 
 
Rel/NF-κB 
deficiency mice B-lineage phenotypes 
nfκb1-/- 
Loss of marginal zone B cells and peritoneal B1 B cells [98]; 
mature quiescent B cells turn over rapidly when activated by LPS 
and CD40; splenic B cells proliferate poorly due to a cell-cycle 
block in G1 and enhanced mitogen-induced apoptosis [104]; nfκb1-/- 
B cells fail to mount a normal humoral response when challenged 
with various antigens [21]  
nfκb2-/- 
Abnormally low numbers of follicular B cells; proliferation is 
moderately reduced in response to LPS, anti-IgD-dextran, and 
CD40; undergo normal class-switch recombination, but generate 
inadequate humoral responses to various T-cell-dependent antigens 
[22, 23] 
relA-/- 
Mice injected with p65-deficient fetal liver cells show a decrease in 
the populations of pro-B cells, pre-B cells, immature B cells, and 
recirculating mature B cells [105]; MZ B cells are partially reduced 
[98] 
relB-/- Crippled in proliferate response, undergo normal IgM secretion and 
class switching [106], defective MZ B-cell development [107] 
c-rel-/- 
Impaired B-cell proliferation in response to range of individual 
mitogens due to a cell-cycle block in G1 and elevated activation-
induced apoptosis [104, 108, 109]; MZ B cells are partially reduced 
[98] 
Table 1-3: B-lineage cells affected in individual Rel/NF-κB mutant mice. 
 
Functional redundancy among these proteins, however, prevents the emergence of clear 
phenotypes. Indeed, the deficiency in different combination NF-κB proteins leads to 
distinct B-cell developmental defects (Figure 1.9). In nfκb1-/-nfκb2-/- double knockout 
mice, B-cell development is blocked at the T1 stage in spleen due to the defects in BAFF 
signaling [31]. It has been shown that BAFF-R can activate the alternative NF-κB 
pathway by inducing p100 processing into active p52 complexes [110]. The combined 
loss of NF-κB1 and RelA results in the absence of B220+ cells in bone marrow.  
Interestingly, this defect does not appear to be cell-intrinsic since it can be rescued by co-
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transplanting nfκb1-/-relA-/- together with wild-type bone marrow into recipient mice [34]. 
In bone marrow of mice reconstituted with c-rel-/-relA-/- fetal liver cells, immature B-cell 
numbers are relatively normal. However, the frequency of splenic B cells is reduced ~10-
fold due to 5–10-fold decreased Bcl-2 expression. This reduction is mainly due to the 
absence of the mature, long-lived B cells although immature and transitional B cells are 
also fewer in numbers [33, 111]. 
 
 
Figure 1.9: Function of Rel/NF-κB members in B-cell development and activation. Rel/NF-
κB transcription factors prevent B-cell apoptosis during maturation and activation by 
transcriptionally regulating distinct sets of Bcl-2-like pro-survival genes at different 
developmental checkpoints in response to various extracellular signals. (Adapted from [112]) 
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1.3  Secondary lymphoid organogenesis 
Primary lymphoid organs, in mammalian bone marrow and thymus, provide 
environments that support the development and the initial maturation of antigen-specific 
lymphocytes and other hematopoietic cells. The secondary lymphoid organs are spleen, 
lymph node (LN), and organized lymphoid tissues associated with mucosal surfaces 
including Peyer’s patches (PP), tonsils, gut-associated lymphoid tissues (GALT), and 
nasal-associated lymphoid tissues (NALT). They provide sites where encounters between 
rare antigen-specific lymphocytes and their cognate antigens can occur efficiently. 
 
1.3.1  Signals in secondary lymphoid organ development  
The development of secondary lymphoid organs is a complex process that depends on the 
correct expression of several molecules within a defined timeframe during ontogeny. The 
anatomic features of secondary lymphoid organs are well defined; however, the signals 
that lead to the establishment and maintenance of this organized structure are only 
beginning to be understood. 
 
1.3.1.1  The role of lymphotoxin (LT) in lymphoid organ formation 
The first signaling pathway shown to be essential for development and organization of 
lymphoid tissue involves signaling through lymphotoxin β receptor (LTβR). The LTβR is 
a member of tumor necrosis factor (TNF) receptor family. LTβR triggering can be 
mediated by membrane-bound LTα1β2 heterotrimers (mLT) and LIGHT. However, in the 
absence of LIGHT, nearly all LNs and PPs develop, indicating that LTα1β2 signaling 
through LTβR has a dominant role in lymphoid organogenesis although LIGHT 
contributes to the formation of mesenteric lymph nodes.  
 
The importance of LTβR signaling pathway for the formation of secondary lymphoid 
organs, such as LN and PP as well as the lymphoid compartment in spleen, has been 
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clearly demonstrated by injections of soluble LTβR-immunoglobulin fusion proteins 
during embryogenesis and by analysis of mutant mice, in which LTβR signaling does not 
take place [113]. Injections of soluble LTβR-immunoglobulin fusion proteins during 
embryogenesis inhibit the lymphoid organ formation at E12.5, blocking the development 
of all LNs and PPs, whereas injections at E15.5 allow the formation of brachial and 
axillary lymph nodes [114]. The complete absence of LN and PP in ltα-/-, ltβ-/-, and ltβr-/- 
mice further supports the crucial role of LTβR signaling in the formation of secondary 
lymphoid organs. 
 
1.3.1.2  NF-κB signaling in secondary lymphoid organ development 
LTβR is predominantly expressed on stromal cells in various lymphoid tissues. Upon 
binding of membrane-bound LTα1β2 heterotrimers, both classical and the alternative NF-
κB activation pathway are engaged. The importance of the alternative signaling pathway 
and the activation of p52/RelB heterodimers in lymphoid organogenesis is illustrated by 
the lack of  LN, PP, and disorganized spleen microarchitecture in nik-/- and aly/aly (a 
point mutation in the gene that encodes NIK) mice [115-117]. In addition, similar 
abnormalities in secondary lymphoid organ formation have been reported in ikkα-/- or 
ikkαAA (NIK phosphorylation sites replaced by alanines), nfκb2-/-, and relB-/- mice, 
although LN development in relB-/- mice seems normal until birth [113, 118, 119]. 
Germinal    centers (GCs) are severely impaired in aly/aly, nfκb2-/-, and relB-/- mice [107], 
whereas nfκb1-/- mice have a much milder defect. In addition, these mice completely lack 
follicular dentritic cell (FDC) networks within B-cell follicles, whereas spleens from 
nfκb1-/- mice develop FDC networks although they are less developed compared to wild-
type controls. Formation of splenic MZ and MZ B cells are also severely impaired in 
different NF-κB-deficient mice. RelB contributes to MZ organization and expression of 
certain chemokines, such as BLC and SLC, by being part of p52/RelB complexes in 
stromal cells downstream of LTβR, and RelB is required for MZ B-cell development in a 
cell autonomous manner. In addition, RelB is essential for the development of MMM. 
nfκb2-/- mice lack MMM and have normal or only slightly reduced numbers of MZM in a 
cell-intrinsic manner. NF-κB1/p50 is required in a cell autonomous manner for the 
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generation of MZ B cells [98]. The loss of either RelA or c-Rel leads to a less severe but 
detectable reduction in MZ B-cell numbers (Table 1-4). 
 
 
Table 1-4: Comparison of spleen phenotypes of mice lacking Rel/NF-κB family members or 
specific upstream signaling components. 
 
The classical NF-κB pathway that triggered upon LTβR involves the activation of 
p50/RelA heterodimers. The role of RelA in lymphoid organogenesis is less well 
understood owing to the embryonic lethality of relA-/- mice, which is caused by massive 
TNF-induced hepatocyte apoptosis around E15. Mice deficient for both RelA and TNFR-
1 (p55) rescue the early lethality and they also lack secondary lymphoid organs, such as 
LN and PP, and an organized splenic microarchitecture [32]. However, the exact 
contribution of RelA to this phenotype is unclear since the lymphoid organ development 
is already affected by the loss of the TNFR-1 pathway. Targeted disruption of the tnfr1 
gene blocks signaling from TNF, LTα3, and LTα2β1, but signaling can still occur via 
LTα1β2 to LTβR. PPs are either absent or reduced in number in tnfr1-/- mice, indicating 
that TNFR signaling plays a role in PP development. It has been reported that the relB 
gene transcription is regulated by NF-κB, particularly by RelA. However, in relA-/- 
fibroblasts, RelB complexes are still induced upon LTβR triggering although at reduced 
levels [17], indicating that RelA is not absolutely required for the induction of RelB 
complexes downstream of LTβR. Taken together, RelA and RelB may function distinctly 
in secondary lymphoid organogenesis rather than RelB simply being a transcriptional 
 23
                                                                                                                            Introduction 
target of RelA.   
 
LTβR signaling also regulates the expression of adhesion molecules and chemokines. 
These molecules seem to be essential for lymphoid organ development. After LTβR 
ligation, activation of p52/RelB heterodimers results in the production of lymphoid 
chemokines CXCL12 (SDF1), CXCL13 (BLC), CCL19 (ELC), and CCL21 (SLC), 
whereas the upregulation of vascular-cell adhesion molecule 1 (VCAM1) requires the 
activation of p50/RelA heterodimers [107, 120]. 
 
1.3.1.3  The complex phenotypes of relB-/- mice  
RelB shares many common features with other Rel/NF-κB proteins. However, only RelB 
contains an N-terminal leuzine zipper motif, which along with the C-terminal non-
homologous transactivation domain participates in full transcriptional activation. High 
levels of RelB expression are restricted to specific region of lymphoid tissues, correlated 
with constitutive basal NF-κB activity in these tissues. Interestingly, relB-/- mice exhibit a 
complex phenotype [25], including multi-organ inflammatory, severe deficits in adaptive 
immunity, splenomegaly, and lack of LNs as well as PPs. Loss of cellular immune 
responses in these mice is consistent with the observed deficit in thymic medullary 
epithelial cells and the loss of functional dendritic cells [27]. Multi-organ inflammation is 
exaggerated in mice also lacking p50, indicating that p50 and RelB cooperate in the 
regulation of genes that limit inflammation [35]. The importance of RelB in lymphoid 
organogenesis is evident in relB-/- mice, particularly in the development of PP and LN 
[17, 118]. Moreover, relB-/- mice unable to form germinal centers (GCs), marginal zone 
structure, and follicular dendritic cell network upon antigen challenge in spleen. Almost 
no MZ B cells develop in relB-/- mice and this defect is cell-intrinsic [107]. These 
findings highlight the role of p52/RelB heterodimers (probably in response to LTβR 
signaling) in the regulation of κB target genes during lymphoid organogenesis and the 
maintenance of intact structure of these tissues. 
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1.4  Conditional gene targeting 
Gene targeting, defined as the introduction of site-specific modifications into the mouse 
genome by homologous recombination, is generally used for the production of null or 
‘‘knockout’’ animals to study gene function in vivo. Homologous recombination of 
foreign DNA with endogenous genomic sequences is a relatively infrequent event in 
mammalian cells compared to random integration. The only efficient gene targeting 
method established presently utilizes pluripotent murine embryonic stem cell (ES) lines. 
Using these cells, selection of rare, homologous recombination ES clones in vitro can be 
accomplished. Gene-targeted ES cells are then injected into blastocysts. They can 
contribute to all cell lineages (including germ cells) of the resulting chimeras. The 
breeding of germline chimeras, which transmit an ES cell derived mutant chromosome to 
their progeny, allows the generation of animals with the desired genetic alteration [121, 
122].  
 
Conditional gene targeting, in contrast, can be defined as a gene modification, which is 
restricted to certain cell types or different development stages of mouse. The conditional 
mutation confined to a particular cell lineage would greatly aid in the determination of a 
gene’s function in that particular cell lineage or tissue. A powerful feature of a 
conditional gene inactivation strategy using the Cre/loxP recombination system is that the 
same loxP sites-flanked mouse can be used for gene ablation in a large number of 
different tissues or at different development stages, by simply mating it with a 
corresponding Cre-transgenic line that displays the desired tissue or temporal specificity 
of expression. Thus, the same genetically modified animal can be used to answer a 
variety of questions relating to the expression and function of the target gene. 
 
1.4.1  Cre-mediated recombination 
The Cre protein is the 38 kDa product of the cre (cyclization recombination) gene of 
bacteriophage P1 and is a site-specific DNA recombinase of the Int family. Cre 
recognizes a 34 bp site on the P1 genome called loxP (locus of X-over of P1) and 
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efficiently catalyzes reciprocal conservative DNA recombination between pairs of loxP 
sites (Figure 1.10).  
 
Figure 1.10: Cre-mediated recombination. The 34 bp loxP consists of two 13 bp inverse 
repeats (black) that flank an 8 bp non-palindromic core sequence (red). This core sequence 
confers directionality to these sites (red arrows). Dimers of Cre catalyze in cis the conservative 
recombination between two directly repeated loxP sites (red arrowheads), resulting in the 
formation of a synaptic structure, the excision of region B, and the juxtaposition of regions A and 
C. If region B is an essential region of a gene, then the recombination event results in gene 
inactivation. (Adapted from [122]) 
 
1.4.2  Strategy for generating conditional gene modification 
The use of the Cre/loxP recombination system requires the generation of both a mouse 
strain harboring a loxP-flanked (floxed) segment of the target gene and a second strain 
expressing the Cre recombinase under the control of certain promoters. A conditional 
mutant is then generated by crossing these two strains so that the floxed target gene is 
mutated in a spatial or temporal manner according to the pattern of Cre expression in the 
particular strain used (Figure 1.11).  
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Figure 1.11: Conditional gene ablation by Cre recombinase. The target endogenous gene is 
modified by homologous targeting in ES cells so that it is flanked by two directly repeated loxP 
sites. In the situations that require removal of the neo gene, a third loxP site is positioned so that 
the neo gene can be excised by transient expression of Cre in ES cells. After identification of 
clones that retain the loxP-flanked target gene, mice are generated from ES cells by standard 
procedures. Mating of the loxP-modified mouse with a Cre-transgenic mouse will generate a 
double-transgenic mouse, in which the loxP-modified gene will be deleted in the tissues in which 
the Cre transgene is expressed. In the example shown, Cre is expressed in the ears (striped) of the 
Cre-transgenic line so that deletion of the loxP-modified target gene is confined solely to the ears 
(white) of the double-transgenic mouse. (Adapted from [121]) 
 
1.4.2.1  Recombination events upon transient Cre transfection   
The flox-and-delete strategy can be used for conditional gene mutation and is especially 
useful if lethality is anticipated in conventional mutants. This type of targeting vector 
contains three loxP sites in the same orientation, two of them flanking the selection 
marker gene and an isolated loxP within one arm of homology. The floxed selection 
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marker for the targeting vector usually is the neo gene or neo/HSVtk genes. After 
identification of the homologous recombinant ES clones, transient Cre expression leads 
to three different recombination products (Figure 1.12). The recombination, which 
happens between the loxP sites flanking the neo gene, leaves one loxP site in the genome 
which generates, together with the isolated loxP site, the floxed version of the target gene 
(type I). The second recombination product (type II), the deletion between the isolated 
loxP site and the inner loxP site flanking the neo gene is usually not of practical use and 
will not be found if ES colonies are screened for G418 sensitivity after Cre expression 
since such colonies retain the neo gene. If the recombination occurs between the outer 
loxP sites, a large deletion is created which is similar to the conventional gene targeting 
(type III). After identification of those transformants in which homologous recombination 
has replaced one copy of the endogenous gene with the mutant variant of the targeting 
construct, the neo gene can be removed by Cre-mediated recombination; leaving behind 
only the 34-bp loxP site forms the floxed allele together with the isolated loxP site. 
Unless placed in a coding exon or another critical region of the gene, the loxP site is 
unlikely by itself to interfere with gene expression. 
 
Figure 1.12: Cre-mediated recombination in homologously recombined ES cells. 
Transfection of a Cre-recombinase encoding plasmid results in different recombination products 
among the introduced loxP sites. Type I recombinants are used to generate mice in which the 
target locus is flanked by loxP sites. M: marker gene; A: a target locus. 
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1.5  Aims 
Deletion of individual members of Rel/NF-κB family does not affect mainstream B-cell 
development although defective B-cell activation upon stimulation is observed, mainly 
due to the increase of apoptosis. The deficiency in different combination of NF-κB 
members indicates a distinct role of NF-κB proteins in B-cell development. In the 
absence of RelB, development and function of particular B-cell subset are impaired. The 
aim of the first project is to understand the role of RelB-specific inhibitor NF-κB2/p100 
and RelB in B-cell development. Towards this goal, p100-/- mice, lacking the inhibitory 
p100 precursor but still expressing active p52 subunit of NF-κB2, will be analyzed with 
an emphasis on the development of mainstream B-cell and other B-cell subsets. 
 
The activation of NF-κB through LTβR is critical for secondary lymphoid organogenesis. 
LTβR signaling induces both classical (p50/RelA) and alternative (p52/RelB) complexes. 
The importance of alternative pathway in lymphoid organogenesis is illustrated by the 
similar phenotypes in mice lacking individual NF-κB members, upstream kinases, and 
receptors. The contribution of RelA in this process is suggested by the lack of LNs and 
PPs in relA-/-tnfr1-/- mice. It is still unclear that which NF-κB activity contributes to which 
part of secondary lymphoid organogenesis. There is also no direct proof that whether 
RelB and/or RelA does function downstream of LTβR signaling in vivo, regulating the 
development of secondary lymphoid organs. The aim of the second project is to generate 
tools to dissect the individual contribution of both NF-κB pathways downstream of LTβR 
signaling in vivo with a specific focus on lymphoid organogenesis. To fulfill this, mouse 
models will be established, in which a specific inactivation of relB or relA in LTβR-
expressing cells could be achieved using gene targeting technology. Phenotypic analysis 
of relBltbr-cre and relAltbr-cre mice will unravel the contribution of classical (RelA 
complexes) and alternative NF-κB pathway (RelB complexes) to LTβR-dependent 
processes on the organic level. The generation of relBflox/flox mice will be useful to 
investigate the specific function of RelB in other cell types, when crossed with different 
Cre-transgenic mice. For example, the role of RelB in B cells could be studied without 
the influence of losing RelB function in other cell types. 
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2  MATERIALS AND METHODS 
2.1  Materials 
2.1.1  Mice 
The generation of p100-/- [36], relB-/-, and nfκb1-/- [22]mice has been previously reported. 
p100-/- and relB-/- mice were mated to generate p100-/-relB+/- and p100-/-relB-/-mice. p100-
/- and nfκb1-/- mice were mated to generate p100-/-nfκb1+/- and p100-/-nfκb1+/- mice. All 
animal were housed and bred under the standard conditions with water and food ad 
libidum in the pathogen free mouse facility of Forschungszentrum Karlsruhe, Institute of 
Toxicology and Genetics. For timed pregnancies, mice were mated and the noon of the 
day vaginal plugs was accepted at 0.5 days post coitus (d.p.c). 
 
2.1.2  Chemicals 
All general chemicals were purchased from Carl Roth GmbH & Co (Karlsruhe), Merck 
(Darmstadt), Sigma Chemie GmbH (Deisenhofen), and Invitrogene GmbH (Karlsruhe) 
and with highest purity grade. 
 
2.1.3  Radiochemicals 
[32α-P]-dCTP (Amersham Life Science) 
 
2.1.4  Primers 
All primers were synthesized by MWG-Biotech AG (Ebersberg) and were of HPSF 
purified grade.  
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2.1.4.1  Primers for real-time PCR 
(Primers with melting temperature (Tm) of 58-60ºC were designed using Primer 
Express Software v2.0 from Applied Biosystems) 
 
774-Pax5-794:    GACATCTTCACCACCACGGAA 
927-Pax5-909:    AGGACTGTGGGCCTGGAAC 
 
599-E2A-618:     GGACATACAGCGAAGGTGCC 
749-E2A-731:     GCCTGACTCAAGGTGCCAA 
 
714-EBF-734:      CCATGTCCTGGCAGTCTCTGA 
865-EBF-847:      TCCATCCTTCACTCGGGCT 
 
690-CD19-710:      AGAGCACCCGGTCAGAGAGAT 
840-CD19-821:      GAGCCACACTGCTGACCTTG 
 
1857-mb1-1877:      ATTGTTTCCCTCAGACACCCC 
2007-mb1-1988:      CATGTCCTGGGTCTGGTTGC 
 
1491-BLNK-1509:    GGAGGCTGAACTGCTCGGT 
1641-BLNK-1622:   CGCAACTAGGGTGTACGGCT 
 
5980-Notch1-5998:     CCAGATCCTGCTCCGGAAC 
6143-Notch1-6123:     AAGCCGACTTGCCTAGGTCAT 
 
804-M-CSF-R-824:     GCTGGAAATCCCCCTAAACAG 
954-M-CSF-R-936:     GAAGTTCATGGTGGCCGTG 
 
456-MPO-474:   CCCAGGCATAAAAACCCGT 
606-MPO-586:   TGAATTCTCCACTTCCCCCAG 
 
897-C/EBPα-917:     GAGCCGAGATAAAGCCAAACA 
 1056-C/EBPα-1037:     GACCAAGGAGCTCTCAGGCA 
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370-PU.1-390:   CCGCAGCTACAGCAGCTCTAT 
420-PU.1-400:   GACGTGCATCTGTTCCAGCTC 
 
β-actin Forward:   TGGCGCTTTTGACTCAGGA 
β-actin Reverse:   GGGAGGGTGAGGGACTTCC 
 
2.1.4.2  Primers for genotyping relBflox/flox mice  
10139-RelB-10146:   TGAGAGTGGATCTCTGTG 
10360-RelB-10342:   TCGATGATTTCTGCGCGA 
 
2.1.4.3  Primers for genotyping ltbr-cretg mice  
ltbr-exon2-forw (270-ltbr-288):   CCCTTATCGCCATAGAAAAC 
ltbr-exon3-rev (448-ltbr-467):   GTTCCAGTGTTCATTATAGG 
cre-rev (3038-cre-3056):    GCGCGCCTGAAGATATAGA 
 
2.1.5  Plasmids 
2.1.5.1  Plasmid gifts (obtained from)  
pLTNT (Dr. H. Schorle), pTVFlox-0 (Dr. P. Zhu), and pGK-Cre (Dr. M. Blum) 
 
2.1.5.2   Plasmid constructs 
pRelBXS11.2-LLTNL, pTVFlox-LRelBXS11.2, and pTVFlox-LTβR-cre 
Plasmid maps are described in the results part of thesis. 
 
2.1.6  Cell culture – cell lines and cell culture media 
Unless otherwise stated, all tissue culture media and PBS used for washing cells were 
purchased from Invitrogen GmbH together with the supplements such as 
Penicillin/Streptomycin and Glutamax. Trypsin was purchased from Difco Laboratories 
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and was diluted to 0.25% in 15 mM sodium citrate and 134 mM potassium chloride, 
which were kept as stocks at -20ºC.  
 
2.1.6.1   Cell lines 
Embryonic stem cells (ES):  E14.1, CJ7, and Kunt I 
Mouse embryonic fibroblasts (EF): home made  
B-cell lines:    BaF3, WEHI 231, and 70Z/3 
 
2.1.6.2   ES Media 
Reagent Volume Catalog  Nr. Store 
D-MEM (1×), liquid - with 
GlutaMAX™ I, Sodium Pyruvate 500 ml Gibco 31966-047 4°C 
GlutaMAX™-I Supplement, 200mM 6 ml Gibco 35350-038 -20°C 
2-Mercaptoethanol (1,000×), liquid 1.2 ml Gibco 31350-010 4°C 
MEM Non Essential Amino Acids 
Solution (100×), liquid 6 ml Gibco 11140-035 4°C 
Penicillin-Streptomycin Solution 6 ml Gibco 15140-114 4°C 
ESGRO® (LIF) [Murine LIF] 1 ml (1,000 u) ESG 1107 -20°C 
FBS 75 ml Biochrom AG S0115 -20°C 
Sodium Pyruvate MEM 100 mM 
liquid 6 ml Gibco 11840-030 4°C 
 
2.1.6.3   EF Media 
Reagent Volume Catalog Nr. Store 
D-MEM (1×), liquid - with Sodium 
Pyruvate 500 ml Gibco 41966-029 4°C 
D-MEM (1×), liquid - with 
GlutaMAX™ I, Sodium Pyruvate 5.5 ml Gibco 25030-024 -20°C 
Penicillin-Streptomycin Solution  5.5 ml Gibco 15140-114 4°C 
FBS 50 ml PAA A15-649 -20°C 
 
 
 33
                                                                                                          Materials and Methods 
 
2.1.7  Bacteria strains 
DH5α (Gibco), TOP10 (Gibco), and JM110 (deficient for Dam and Dcm, Stratagene) 
 
2.2  Methods 
The following routine molecular biology methods were performed according to standard 
protocols (Sambrook and Russell, 2001): 
Mini plasmid preparation, restriction digests of DNA, spectrophotometric quantification 
of nucleic acids, phenol: chloroform extraction, preparation of electrocompetent bacteria, 
ligation reactions, blunting reaction with T4 DNA polymerase, dephosphorylation of 
plasmids with CIP, electroporation of bacteria, precipitation of nucleic acids, and basic 
PCR reaction 
 
The following routine molecular biology manipulations were performed by using kits or 
commercially available reagents according to the manual. 
Site-directed mutagenesis (QuickchangeTM Site-Directed Mutagenesis Kit, Stratagene) 
Cloning of long (3-10 kb) PCR products (TOPO® XL PCR Cloning Kit, Invitrogen) 
Cloning of PCR products (TOPO TA Cloning®, Invitrogen) 
Labeling of DNA by random priming (rediprimeTM II Kit, Amersham) 
Large scale plasmid preparation (Qiagen Plasmid Maxi Kit, Qiagen) 
Total RNA extraction (NucleoSpin RNA II kit, Macherey-Nagel Company) 
Isolation and purification of DNA from agarose gel (EasyPure DNA purification Kit, 
Biozyme) 
 
The methods described in detail below are those developed or modified in this thesis. 
 
 34
                                                                                                          Materials and Methods 
2.2.1  Preparation of single cell suspensions from lymphoid organs 
Different lymphoid organs were collected. Tissues were pushed through a metal sieve 
into 6 cm petri dishes with FACS buffer using plunger. The cell aggregates, which were 
collected into petri dishes, were passed through 10 ml syringe with a 21 Gauge needle for 
3-5 times. Cells were followed being lysated in ACK lysis buffer at room temperature 
(RT) for 5 minutes (min). After two times washing with FACS buffer, cells were finally 
resuspended in 10 ml FACS buffer and passed through cell strainer with 40 µm pore size. 
An aliquot of 10 µl cells was taken into trypan blue solution for counting trypan blue 
negative cells using hemocytometer. All the centrifugation steps were performed at 1,500 
revolutions per minute (rpm) for 5 min at 4oC. 
FACS buffer:  PBS with 2% fetal calf serum (FCS), kept at 4oC 
ACK lysis buffer: 0.15 mM NH4Cl, 1 mM KHCO3, and 0.1 mM Na2EDTA pH 7.2-7.4, 
adjusted with 1 N HCl, filter-sterilized, and stored at RT 
 
2.2.2  Analysis of cells by flow cytometry 
Flow cytometry was performed using a Becton Dickinson FACSstar. All the monoclonal 
antibodies (mAbs) used for flow cytometric analysis were purchased from BD 
biosciences. FITC-conjugated mAbs were diluted 1:100, PE-conjugated mAbs 1:200, and 
Cy-conjugated mAbs or biotin-conjugated mAbs 1:300 before use. Single cell 
suspensions were washed twice with FACS buffer. The following flourochrome 
conjugated mAbs were used: anti-B220-Cy/PE/FITC (clone RA3-6B2), anti-CD4/FITC 
(clone RM4-5), anti-CD8/PE (clone 53-6.7), anti-CD11b/FITC (clone M1/70), anti-
CD19/PE (clone 1D3), anti-CD21-FITC (clone 7G6), anti-CD23-PE (clone B3B4), anti-
CD43/FITC (clone S7), anti-CD117(c-kit)-Biotin (clone 2B8), anti-CD127(IL-7R)-Biotin 
(clone B12-1), anti-Gr-1-PE (clone RB6-8C5), anti-IgM-Bio/FITC (clone R6-60.2), anti-
IgD-FITC (clone 11-26), anti-Thy1.2-FITC (clone 53-2.1), anti-CD45.1-Biotin (clone 
A20), and anti-CD45.2-Biotin (clone 104). Biotinylated mAbs were detected with 
Streptavidin-PerCP (diluted 1:300).  
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Staining with mAbs was performed in a standard method. In brief, 0.5 ×106 cells were 
stained with different combinations of mAbs in FACS buffer in U-bottom 96-well plate 
(CellStar, Griener) on ice for 30 min. After that, cells were washed two times with FACS 
buffer and fixed with 4% formaldehyde in PBS for 10 min at RT. After washing for two 
times, cells were resuspended in FACS buffer for analysis or for storage at 4oC. Data 
were analyzed using CELLQuest ProTM software (BD Bioscience). 
 
Apoptotic cells were detected by Annexin-V-FITC (BD biosciences) according to the 
manufacturer’s specifications. Briefly, 1×106 cells were suspended with 100 µl 
incubation buffers in U-bottom 96-well plate. After washing, cells were stained in 
Annexin-V staining solution. After incubating for 15 min at RT, cells were washed twice 
with 200 µl of incubation buffer and finally resuspended in 100 µl incubation buffer for 
flow cytmetric analysis. Data were analyzed using CELLQuest ProTM software (BD 
Bioscience). 
Incubation buffer:  10 mM HEPES/NaOH, pH 7.4, 120 mM NaCl, and 5 mM CaCl2 
Annexin-V staining solution: 10 ml of Annexin-V-FITC stock and 20 µl of propidium iodide 
stock (50 µg/ml) were diluted in 1500 µl incubation buffer that is 
sufficient for 15 samples  
 
2.2.3  Purification of pro-B Cells 
Bone marrow (BM) cells were first stained with anti-CD19-PE mAb (Pharmingen, 2-2.5 
µl/10×106 cells) in FACS buffer (90 µl/10×106 cells) on ice for 30 min. After washing 
with excess FACS buffer, cells were resuspended in MACS buffer (90 µl/10×106 cells) 
and incubated with anti-PE MicroBeads (Miltenyi Biotech, 10 µl/10×106 cells) for 15 min 
at 6-10oC. After washing with excess MACS buffer, cells were resuspended in 1 ml 
MACS buffer, passed through cell strainer (40 µm pore size) on to the MACS negative 
selection column (LD; Miltenyi Biotech), and depleted CD19+ B cells as per the 
manufacturer’s specifications. Afterwards the CD19- B-cell portion was collected and 
recounted. Cells were then stained with anti-B220-Cy5 mAb (Pharmingen) in FACS 
buffer on ice for 30 min and incubated with anti-Cy5 MicroBeads (Miltenyi Biotech, 10 
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µl/10×106 cells) for 15 min at 6-10oC. After washing with excess MACS buffer, cells 
were resuspended in 1 ml MACS buffer and passed through cell strainer (40 µm pore 
size) on to the MACS positive selection column (MS; Miltenyi Biotech) to obtain the 
B220+ B cells. An aliquot of cells from each step of purification procedures was used for 
flow cytometric analysis to check the purity.  
MACS Buffer: 0.5% Bovine Serum Albumin (BSA) in PBS without Ca2+ and 
Mg2+ and 2 mM EDTA 
 
2.2.4  Extraction and analysis of RNA 
2.2.4.1  Total RNA isolation from cells 
5×106 cells were pelleted in 1.5 ml eppendorf tubes and resuspended in 350 µl lysis 
buffer RA1, containing 3.5 µl β-mecaptoethanol. The total RNA isolation was performed 
using ‘NucleoSpin RNA II’ kits purchased from Macherey-Nagel Company. The 
procedures were performed following the manufacturer’s instructions. Contamination 
DNA was removed by a DNase I solution. Total RNA was kept frozen at -80ºC.  
 
2.2.4.2  Determination of RNA concentration and agarose gel electrophoresis 
of RNA samples 
RNA concentration was determined spectrophotometrically (Eppendorf 
spectrophotometer) by taking readings at 260 nm against a blank, ddH2O. A solution of 
50 µg/µl DNA or 40 µg/µl RNA in a 1 cm quartz cuvette will give an absorbance of 1 at 
260 nm. The concentrations were calculated according to absorbance values and total 
volume of RNA solution. Protein contamination during the isolation procedure was 
assessed by A260/A280 ratio with a value of 1.7 or greater as an indication of a good 
purity. The quality of RNA samples and genomic DNA contamination were further 
assessed by agarose gel electrophoresis. Aliquots of RNA samples (minimum 0.5 µg) 
were diluted in water and 10 × gel loading buffer. 0.8% (w/v) agarose gels containing 
ethidium bromide to a final concentration 100 µg/ml were prepared in 1 × TAE buffer. 
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Samples were loaded and observed by illumination with UV light and photographs were 
taken using an Eagle Eye photocamera system (Stratagene). 
10 × gel loading buffer: 0.25% bromophenolblue, 0.25% xylene cyanol FF, and 15% 
Ficoll in water; kept at RT, final 1 × concentration 
1 × TAE buffer:  0.04 M Tris-acetate and 0.01 M EDTA 
 
2.2.4.3  First strand cDNA synthesis of total RNA samples 
First strand complementary DNA (cDNA) was synthesized from total RNA by using M-
MLV Reverse Transcriptase (Promega) as described by the manufacturer. 1-5 µg total 
RNA was added in a 1.5 ml sterile RNase-free Eppendorf tube together with 0.5 µg oligo 
(dT) 12-18 (New England Biolabs). The volume was completed to 14 µl with sterile 
ddH2O. The reaction mixture was heated to 70ºC for 10 min to melt secondary structure 
within the template, and then quickly chilled on ice for 5 min. Following brief 
centrifugation, 5 µl M-MLV 5 × Reaction buffer, 5 µl 10 mM dNTP mix (Peq Lab) (10 
mM each dATP, dGTP, dCTP, and dTTP at neutral pH), and 200 units M-MLV Reverse 
Transcriptase were added. The samples were incubated at 42ºC for 60 min following heat 
inactivation at 70ºC for 15 min. Then the cDNA samples were ready for amplification by 
PCR. The samples were diluted 5-fold (final volume 100 µl) with sterile ddH2O before 
they were used as template for amplification. 
 
2.2.4.4  Real-time PCR 
5 µM primers mix was prepared by adding 20 µl sense (100 pmol/µl) and 20µl antisense 
(100 pmol/µl) primers to 360 µl sterile ddH2O. For each template (cDNA), three 
independent PCR reactions were performed (triplet) to avoid pipetting errors. Run a 
housekeeping gene (β-actin) and the genes of interest together. Run NTC (without adding 
template) as negative control as well. The reaction was set up in 20 µl volume, containing 
10 µl 2 × SYBR-Green Mix, 4 µl Primermix, 4 µl template, and 2 µl ddH2O. Run the 
PCR with protocol SYBR-40 (50°C 2 min, 1 cycle; 95°C 10 min, 1 cycle; 95 °C 15 s→ 
60 °C 30 s → 72 °C 30 s, 40 cycles; 72°C 10 min, 1 cycle). Analyze the real-time PCR 
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result with the SDS 7000 software. Check if there is any bimodal dissociation curve or 
abnormal amplification plot. Data were exported and analyzed with Pfaffel methods that 
provide a means for quantification of a target gene transcript in comparison to a reference 
gene. 
 
2.2.5  Generation of bone marrow chimeras 
Bone marrow cells were isolated from arm bones, tibiae, and femora of 3-week-old wild-
type and p100-/- mice. Bones were first thoroughly cleaned and rinsed with 70% alcohol 
and washed extensively in sterile PBS. The ends of the bones were cut off and the bone 
marrow cells were flushed out with PBS into a petri dish containing 1-2 ml sterile PBS 
using a 2 ml syringe with a 23 Gauge needle. The cells were then passed through the 
same syringe for additional 2-3 times and an aliquot of cells was used for counting the 
number of cells. Up to 4-6 × 106 cells were injected intra venous (i.v.) per mouse in 
different combinations of donor and recipient mice as described in the results section. 
Before injection, around 6-week old recipient mice were irradiated with 2 × 550 rad with 
3 hours interval and rested for 4-6 hours after the second irradiation. After the injection of 
bone marrow cells, mice were kept under pathogen free conditions and were analyzed 
after 6 weeks. For the analysis of chimerism, peripheral blood was collected by cardiac 
puncture at necropsy and immediately transferred into 15 ml falcon tubes containing 10 
ml of PBS with 5mM EDTA and centrifuged at 1,500 rpm for 5 min at 4ºC. The pellets 
were resuspended in 2 ml of ACK lysis buffer and kept at RT for 5 min and then 
centrifuged. ACK lysis was repeated and the pellets were washed two times with FACS 
buffer and the leukocytes were resuspended in 100 µl FACS buffer. The cell suspension 
was transferred to eppendorf tubes and centrifuged at 2,000 rpm for 5 min at 4oC and the 
pellets were resuspended in PBND buffer containing protinase K and kept on an 
incubator shaker at 55ºC for 2-3 hours. The lysates obtained were used for analysis by 
PCR to check the chimerism. 
For the generation of mixed bone marrow chimeras, bone marrow cells from wild-type 
(CD45.1+) and p100-/- mice (CD45.2+) mice was isolated and 3 × 106 cells from each 
mouse were mixed and injected i.v. into irradiated either CD45.1+ or CD45.2+ wild-type 
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recipients. The mice were analyzed after 6 weeks. For the analysis of chimerism of the 
mixed bone marrow chimeras, lymphocytes were stained with anti-CD45.1 or anti-
CD45.2 mAb and were analyzed by flow cytometry.  
PBND buffer: PCR buffer with nonionic detergents; 50 mM KCl, 10 mM Tris-
HCl pH 8.3, 2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% v/v NP-
40, 0.45% v/v Tween-20, and 0.1 µg/ml Proteinase K (3 µl from 
10 mg/ml stock); this buffer was kept at 4oC without Proteinase 
K which was added just before use. 
 
2.2.6  Extraction and analysis of proteins 
2.2.6.1  Preparation of nuclear and cytoplasmic fractions 
Cells were and pelleted in a 1.5ml Eppendorf tube. Supernatant was aspirated and cells 
were gently resuspended in 400 ml buffer A. The sample was incubated on ice for 15 
min, and then 25 µl 10% NP-40 was added, vortexed vigorously for 20 seconds, and 
centrifuged at 13,000 rpm for 1 min at 4ºC. At this step, the supernatant contains 
cytoplasmic RNA and proteins and pellet contains nuclei and cell debri. An aliquot of 
supernatant, 200-300 µl was transferred to a new tube as cytoplasmic fraction. The 
nuclear pellet was washed once with 200 µl buffer A gently, buffer was removed and 60 
µl of buffer C was added without resuspending. The sample was then placed on an 
Eppendorf shaker for 15 min at 4ºC to ensure vigorous mixing such that the pellet 
remains intact and floats around. Following centrifugation at 13,000 rpm for 5 min at 
4ºC, 50 µl of nuclear fraction was recovered and protein concentration was determined. 
Cytoplasmic and nuclear fractions were stored at -80ºC. 
Buffer A:  10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM 
EGTA, 1× proteinase inhibitors, and 2.5 mM DTT 
Buffer C:  20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 25% 
glycerol, 1 × proteinase inhibitors, and 2.5 mM DTT 
Proteinase inhibitors:  One tablet in 2 ml ddH2O gives 25 × stocks (Roche) 
Both buffers were stored at 4ºC without proteinase inhibitors and DTT. 
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2.2.6.2  Protein concentration determination 
Protein concentration was determined by BioRad microassay procedure following the 
manufacturer’s instructions. Bovine IgG was used as a protein standard. Several dilutions 
of standard were prepared (1-25 µg/µl). In dry cuvettes, 800 ml diluted standards or 
appropriate amount of samples (2-3 µl cytoplasmic or nuclear extract) diluted in 800 ml 
ddH2O were placed. 200 ml Dye Reagent Concentrate (5 × stock, BioRad) was added and 
gently mixed. For blanks, 800 ml ddH2O was used. After 5 min RT incubation, OD595 
measurement was performed and a standard curve (concentration in mg/ml versus 
OD595) was plotted to determine the concentrations of extracted samples. 
 
2.2.7  Electro-mobility Shift Assay (EMSA) 
2.2.7.1  Preparation of probes 
Following single stranded oligonucleotides were used: 
Oct-1 up: 5’-GAT CCT GTC GAA TGC AAA TCA CTA GAA A-3’ 
Oct-1 lo: 5’-GAT CTT TCT AGT GAT TTG CAT TCG ACT C-3’ 
Igκ up: 5’-GAT CCA GAG GGG ACT TTC CCA CAG GA-3’ 
Igκ lo:  5’-GAT CTC CTC TGG GAA AGT CCC CTC TG-3’ 
 
2.2.7.1.1  Annealing of oligonucleotides 
Following reaction mix was prepared: 
2 µl  each single stranded oligo (100 pmol/ml) 
200 µl  TE (pH 7.5) 
2 µl  NaCl (5 M) 
(1 pmol/ml oligo concentration in the final volume of 206 µl) 
The reaction was incubated at 80ºC for 15 min and left at RT O/N. 
 
2.2.7.1.2  Radioactive labeling of the annealed oligonucleotides 
Following reaction mix was prepared: 
10 µl  ddH2O 
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2 µl  annealed oligo (2 pmol total) 
2 µl  10 × REACT 2 buffer (Invitrogen) 
2 µl  dNTPs (0.5 mM each without dCTP) 
3 µl  32P-dCTP (10 µCi/µl) 
1 µl  Klenow fragment (6.5 U, Invitrogen) 
The reaction was in a total volume of 20 µl and was incubated at RT for 20 min. 
 
2.2.7.1.3  Purification of radioactive labeled probes 
10 µl of blue dextran solution (0.7% (w/v) in water) was added to the labeling mix. 
Sephadex G-50 (Sigma) in TE buffer was used to prepare 1 ml column in 1 ml syringe 
the bottom of which was plugged with glass wool. Labeling mix with blue dextran was 
added on the column and unincorporated radioactivity was left in the column by eluting 
200-400 µl blue solution (DNA complexed with blue dextran) in TE. One µl of this elute 
was measured using scintillation counter 1211 Minibeta (Wallac). A total of 20,000-
50,000 cpm per reaction was used for bandshift assay. 
 
2.2.7.2  EMSA Assay 
Following solutions are required: 
5 × Binding Buffer (BB): 50 mM Tris-HCl, 250 mM NaCl, 5mM EDTA, and 25% 
glycerol; kept at RT and before use DTT is added to a final 
concentration of 25 mM 
Buffer C   with 1 × proteinase inhibitors and 2.5 mM DTT 
Unspecific competitors: Sonicated calf thymus DNA (1 µg/µl) for Igκ bandshift or 
dI: dC homopolymer (1 µg/µl; Sigma) for Oct-1 bandshift 
 
Rabbit anti-Rel/NF-κB polyclonal antisera for EMSA 
preimmune serum (PI): KD 57 or rabbit serum (Sigma):  
anti-p50:   KD 57-8: anti-p50 
anti-p52:   KD 38-2:  
anti-p65 (RelA):  KD 13-3:  
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anti-RelB:   KD 6-8 or RR 2-8:  
 
All working solutions and binding reactions should be prepared on ice, 5 × BB and buffer 
C were prepared on ice before setting up the binding reactions. Below are the components 
of a binding reaction: 
nuclear extract solution 5 µl (2-4 mg extract) 
5 × BB (final 1×)  4 µl  
competitor (0.4 µg (0.4 µl/reaction) calf thymus (1/10) or 2 mg (2 
ml/reaction) dI: dC (1/2) for 4 mg nuclear extract) 
antiserum    for antibody challenge reactions only 
oligo    20,000-50,000 cpm  
ddH2O   complete the volume to 20 µl 
 
Preferentially, premixes were prepared for each oligo shift by adding 5 × BB, competitor 
and ddH2O the total amounts of which were determined according to the total number of 
reactions. Then, the mix was distributed to precooled tubes, followed by addition of 
appropriate volumes of buffer C and protein extract for each sample. For antibody 
challenge reactions, 1 µl of appropriate antiserum (see above for antisera used) was added 
and the reactions were incubated on ice for 10 min. The radioactively labeled probe was 
then added and the reactions were kept at RT for 20 min. Once complete, 2 µl 10 × gel 
loading buffer per reaction was added and the reaction mix was loaded onto 5% gel. 
While the binding reactions were incubated, the wells of the gel were washed and pre-run 
was performed at 150 V for 10 min using 0.25 × TBE as running buffer. A typical run is 
at 150 V for 2-3 h at RT. Then the gel was dried at 80ºC for 30 min and exposure was 
performed using Hyperfilm MP (Amersham). 
5% polyacrylamide gels: 8.3 ml acrylamide: bisacrylamide (30%), 2.5 ml 5 × TBE (final 
0.25 ×), and 39.2 ml ddH2O, total volume 50 ml. 
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2.2.8  Southern Blotting 
2.2.8.1  Electrophoresis of DNA through gels 
0.8% agarose gel was prepared by dissolving the corresponding amount of agarose in 
TAE and the solution was cooled to 60ºC in a water bath. Samples (digested with 
restriction enzymes) were loaded. The electrophoresis was performed at 100 V (5 V/cm) 
for 2-3 h. The gel was then photographed with a ruler under UV light. 
10 × gel loading buffer: 1 mM EDTA pH 8.0, 0.25% (w/v) bromophenol blue, 0.25% 
(w/v) xylene cyanol, and 50% (v/v) glycerol 
 
2.2.8.2  Transfer of DNA from gel to membrane 
The gel was depurinated in 0.25 M HCl for 20 min and denatured in 0.4 N NaOH for 20 
min until the gel pH down to < 9.0. Then DNA was transferred to membrane (Hybond-
N+, Amersham) with 0.4 N NaOH using a capillary blotting method. After overnight 
(O/N) transfer, the membrane was rinsed with 2 × SSC. UV light cross linking (UV-
crosslinker using Auto-Crosslink program, Stratagene) was then performed for the air-
dried membrane to immobilize the DNA.  
20 × SSC: 175.3 g NaCl, 27.6 g NaH2PO4, and 7.4 g EDTA dissolved in 
800 ml water and pH adjusted to 7.4 with NaOH 
 
2.2.8.3  Radioactive labeling of DNA probes 
Radioactive labeling of DNA probes was performed with a rediprimeTM II Kit according 
to instructions of manufactures. The purification of the radioactive labeled probe is 
describe in 2.2.7.1.3 
 
2.2.8.4  Hybridization and analysis 
The membrane was placed DNA-side up in a hybridization tube and was pre-hybridized 
in 20 ml of Church buffer at 68ºC with rotation for 2-3 h in a hybridization oven 
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(Amersham). The probe (purified and labeled) was denatured at 95ºC for 5 min and snap 
cooled on ice. The hybridization was carried out by addition of appropriate amount of 
radioactively labeled probe for 12-18 h at 68ºC. The membrane was washed two times for 
20 min each at 68ºC in 2 × SSC and 0.5 × SSC containing 0.1% SDS. Finally, the 
membrane was air dried and exposed to Hyperfilm MP Films (Amersham) at -80ºC for 
several hours to days. Quantifications were performed with a Fuji film FLA-3000 
fluorescent image analyzer. 
Church buffer:  1M NaPO4 pH 7.2, 7% SDS, and 1 mM EDTA 
 
2.2.8.5  Stripping DNA probes 
To allow reuse of the Southern blots, radioactively labeled DNA probe was stripped by 
incubating the membranes in a strip buffer (0.1 × SSC, 1% SDS) at 95ºC for 20 min. The 
process can be repeated in case a strong radioactivity remained. The membranes were 
them used for reprobing from the prehybridization as usual.  
 
2.2.9  Isolation of genomic DNA from cells 
Cells were grown to confluency in the 0.2% gelatin-coated 96-well plates, washed with 
PBS, and lysated in 50 µl genomic DNA lysis buffer per well. The lysates were incubated 
at 55ºC with shaking for at least 3 h or overnight. After a brief centrifuge, 100 µl of ice-
cold ethanol were added and mixed on a shaker at RT until DNA was visible. Then the 
DNA was pelleted by centrifugation at 2,000 rpm for 30 min. After wash with 70% 
ethanol twice, air-dry the DNA. Finally, the DNA was dissolved in H2O or restriction 
digestion mixtures. 
Lysis buffer: 10 mM Tris Ph 7.5, 10 mM EDTA, 10 mM NaCL, 0.5% sarcosyl 
(N-lauroylsarcosine; Sigma), and 1 mg/ml proteinase K (add 
immediately before use) 
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2.2.10  Preparation DNA for pronucleus injection 
1% agarose gel containing ethidium bromide was prepared. Samples (digested with 
restriction enzymes) were loaded. The electrophoresis was performed at 100 V (5 V/cm) 
for 2-3 h. The band of interest was cut out and placed into dialysis tubing (flat width 25 
mm), which was sealed at one end with a clamp. 350 µl TE was filled into the tubing, the 
air bubbles were removed, and another end was also sealed.  This array was placed into 
an eletrophoresis chamber filled with TAE in such a manner that the DNA could 
electrophoretically move from the gel slice into TE inside the tubing. The TE containing 
the eluted DNA was pipetted out and extracted subsequently with phenol-chloroform. 
The DNA was then dissolved in injection buffer to a final concentration 2 ng/µl. 10-20 µl 
DNA was checked on a gel to verify the concentration and purity. The remaining DNA 
was passed through a 0.22 µM steril filter and aliquoted directly into sterile Eppendorf 
tubes. 
Injection buffer:  10 mM Tris pH 7.5-8.0 and 0.1 mM EDTA 
 
2.2.11  Cell culture  
2.2.11.1  Mammalian cells other than ES cells 
All cells were maintained at 37ºC in an incubator (Forma Scientific, labortect GmbH) 
with 5% CO2 and 95% humidity. Cells were grown on appropriate sized petri dishes and 
plates (Greiner Labortechnik). 
 
2.2.11.1.1  Primary Pro-B cell  
Purified murine pro-B cells were grown on a semi-confluent layer of γ-irradiated (3,000 
rad) ST2 cells in IMDM supplemented with 10% fetal calf serum, 2 mM glutamine, 50 
µM β-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin. IL-7, IL-3, Flt-
3, SCF, M-CSF, and GM-CSF (10 ng/ml each PeproTech EC Ltd.) was added to culture 
according to different purposes of the experiment. 
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2.2.11.1.2  B-cell lines  
All cells were grown in RPMI 1640 supplemented with 7.5% fetal calf serum, 2 mM 
glutamine, 10 mM HEPES, 2 mM pyruvate, 50 µM β-mercaptoethanol, and 50 µg/ml 
gentamycin. The Ba/F3 cells were grown in RPMI 1640 as above supplemented with 10% 
of IL-3 containing WEHI 231-conditioned media.  
 
2.2.11.2   ES cells 
2.2.11.2.1 Preparation of feeder cells for ES-cell culture 
E14.5 pregnant mouse (CD44+/-) was sacrificed and its abdomen was swabbed by 70% 
ethanol. After opening up abdomen, uterus was removed and placed in a Petri dish with 
PBS. Then the embryos were removed from uterus an extra-embryonic membranes as 
well as intestine, liver, heart, lung, and head were cut out. The carcasses were washed in 
PBS again and transferred to a new dish with 0.25% trypsin solution. After mincing with 
scalpel blades, the mushy tissues were incubated in a total volume of 15 ml trypsin 
solution at 37ºC for 30 min. To obtain single feeder cells, a cell strainer was used to filter 
the minced tissues. The cells were then resuspended in the medium and plated onto 15 cm 
dishes (about one embryo per dish). The feeder cells can be split for propagation or 
frozen down at this stage. Mitotically inactivated cells prepared by gamma ray irradiation 
severed as feeder cells for ES cell culture. 
 
2.2.11.2.2  ES cell culture 
ES cells were cultured on the top of confluent feeder cell layer on 0.2% gelatin (G-9391, 
Sigma) coated dishes (Corning® 100mm TC-Treated Culture Dish, Item #430167). The 
incubator used for ES cell culture was with the conditions of 5% CO2 and 90% humidity. 
Thorough typsinization (to generate single cell suspension) and a daily medium feeding 
interval were performed to avoid the differentiation of ES cells. A centrifugation speed of 
1,000 rpm was used for spin down of ES cells. The freezing medium for ES cells was 
80% FCS and 20% DMSO. Other conditions for ES cell culture and storage were 
basically the same as those for normal mammalian cells shown above. 
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2.2.11.2.3  Electroporation of ES cells 
ES cells were split one day before transfection to allow cells in a logarithmic growth 
phase. Cells (about 1 × 107) were trypsinized, replated for 15 min, washed with cold E-
buffer twice, and resuspended in 0.8 ml E-buffer. After transferring to a pre-cold cuvette 
(4 mm, peQLab), cells were mixed with 25 µg of linearized targeting vector. 
Electroporation was performed with a pulse of 400 V and a capacity of 250 µF in a Bio-
Rad gene pulser (Bio-Rad). Typically, a time constant was between 3.5-6 ms. The cuvette 
was allowed to stand on ice for 10 min before seeding cells on the 10 cm dishes. The 
selection was started by addition of G418 (250 µg/ml, Gibco BRL11811-023) 24 h after 
electroporation and ganciclovir (2 µM, Sigma G2536) 48 h after electroporation, and 
maintained for 7-10 days. The resistant ES colonies were then picked under microscope 
and cultured for freezing and DNA preparation. 
E-Buffer:   PBS with 5mM HEPES, pH7.05 
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3  RESULTS 
3.1  The role of p100 and RelB in B lymphopoiesis 
One of Rel/NF-κB family members, RelB, has been shown to play an important role in 
mature B-cell activation and MZ B-cell development. However, whether RelB functions 
in the development of mainstream B cells has not been well defined. NF-κB2/p100 
functions as a specific inhibitor of RelB in alternative NF-κB activation pathway. 
Therefore, mice lacking the potent RelB inhibitor p100 are good model systems (see 
Figure 1.3) for intensively studying the function of p100 and RelB with respect to B-cell 
development.  
 
3.1.1  Defective B lymphopoiesis in p100-/- mice 
3.1.1.1  Lack of the inhibitory p100 precursor results in reduced number of B 
cells in the periphery 
The effect of p100 on B-cell development was first studied in spleen, which contains a 
high proportion of B lymphocytes. Flow cytometric analysis was performed using 
antibodies that recognize different lineage-specific cell surface markers. The B 
lymphocytes were identified by the presence of pan-B cell marker B220 (CD45R).  
 
Spleens of 3-week-old p100-/- mice were anemic and approximately 2–3-fold smaller than 
that in wild-type mice. Out of five independent experiments on 3-week-old mice, an 
approximately 2-fold reduction of the B220+ cell population and, correspondingly, a 2-
fold increase of Thy-1.2+ T cells in spleen were observed by flow cytometry (Figure 3.1 
A). However, the absolute number of Thy-1.2+ T cells remained unchanged due to the 
reduced number of whole lymphocytes in spleen.  
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Furthermore, splenic B cells were examined by the surface expression of 
immunoglobulin molecules. In mutant mice, the reduction of B cells took place mainly in 
the B220+IgM+ B-cell pool with a mean frequency of 21.7 ± 1.4% compared to 39.1 ± 
4.7% in wild-type mice. The B220+IgM- B cells showed only a mild reduction from 11.6 
± 0.5% in wild-type mice to 9.9 ± 1.7% (Figure 3.1 B). Similar results were observed in 
lymph nodes (LN) and peripheral blood (PBL) (data not shown). Thus, the lack of p100 
in mice results in a diminished number of B lymphocytes in the periphery.  
 
 
 
Figure 3.1: Reduction of B lymphocytes in the periphery due to p100-deficiency in mice. (A) 
Splenocytes were isolated from 3-week-old wild-type (left panels) and mutant mice (right panels) 
and were analyzed for the expression of B220 and Thy-1.2 by flow cytometry.  (B) B-cell profiles 
in spleen (SP) were examined by flow cytometry after staining with anti-B220 and anti-IgM 
monoclonal antibodies (mAbs). Percentages of relevant populations are indicated. Numbers 
indicate mean values (%) ± SD from five mice. 
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3.1.1.2  Lack of p100 results in B-cell developmental arrest at an early stage  
Despite the moderate reduction of B lymphocytes in the periphery in 3-week-old p100-/- 
mice, a noted decrease of B lymphocytes in bone marrow was detected by flow 
cytometry. The percentage of B220+ cells was reduced almost 5-fold compared to control 
littermates (p100-/-, 10.99 ± 2.0% vs. wild-type, 50.94 ± 2.1%). The reduction of bone 
marrow B cells was observed in both B220+IgM- and B220+IgM+ B-cell populations 
(Figure 3.2 A). B220+IgM- cells in bone marrow are composed of B-lineage precursors. 
B220+ precursors start expressing IgM when they differentiate into the immature B-cell 
stage (see Figure 1.5).  
 
The early phase of B-cell development can be divided into different stages according to 
the expression of specific cell surface markers (see Figure 1.5). The transition from the 
pre-pro-B stage (Fr. A) to the early pro-B stage (Fr. B) is characterized by the expression 
of CD19 [52, 53]. Thus, CD19 expression on B lymphocytes in p100-/- mice was 
examined to determine the developmental stage at which the B-cell differentiation was 
blocked.  
 
As shown by flow cytometric analysis after staining with anti-B220 and anti-CD19 
mAbs, the B220+CD19+ double-positive cells (Fr. B) were dramatically (~8-fold) reduced 
in 3-week-old mutant mice with a mean frequency of 6.15 ± 2.1% compared to 46.5 ± 
3.1% in wild-type mice. The percentage of the B220+CD19- population (Fr. A), however, 
was comparable between mutant and wild-type mice (Figure 3.2 B). Moreover, the 
B220+CD19- cells from either mutant or wild-type mice were IL-7R+CD43+c-Kitlow (data 
not shown), characterizing B-cell progenitors at the Fr. A stage.  
 
Thus, the lack of p100 in mice causes a nearly complete developmental block in B 
lymphopoiesis at the transition stage from pre-pro-B (Fr. A) to early pro-B (Fr. B), which 
is indicated by the massive reduction of B220+CD19+ cells in bone marrow (Figure 3.2 
C). Therefore, NF-κB2/p100 is indeed involved in the development of mainstream B 
cells.  
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Figure 3.2: B-cell development is arrest at an early stage in mice lacking p100. (A) Flow 
cytometric analysis of bone marrow (BM) cells from 3-week-old wild-type and p100-/- mice. 
Single cell suspensions were prepared and analyzed for the expression of the indicated cell 
surface markers B220 and IgM. (B) B220 and CD19 expression were analyzed. Lymphocytes 
were gated for the analysis. Percentages of relevant populations are indicated. (C) Schematic 
representation of the developmental stage at which the B-cell differentiation was arrested in p100-
/- mice. Vertical bar (in red-color) indicates the development block.  
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3.1.1.3  B-cell developmental defect in p100-/- mice is cell-intrinsic 
To examine whether the B-cell developmental arrest is a hematopoietic defect or a defect 
in the stromal compartment that supports B-cell differentiation, bone marrow 
reconstitution experiments were performed. After lethal irradiation, wild-type recipients 
were reconstituted with wild-type (wt→wt) or p100-/- bone marrow cells (p100-/-→wt) to 
generate bone marrow chimeras. Mice were checked for their chimeric status by PCR 
genotyping from peripheral blood leukocytes or tail clips for further experiments. 
Chimeras were analyzed six weeks after the bone marrow transplantation.  
 
In bone marrow, the percentage of B220+CD19+ double-positive cells was reduced 
dramatically in p100-/-→wt chimeras, 4.65 ± 1.1% vs. 40.35 ± 3.2% in wt→wt chimeras. 
The percentage of B220+CD19- cells in p100-/-→wt chimeras was comparable to that in 
wt→wt chimeras, though (Figure 3.3 A). This profile was exactly same as what had been 
observed in p100-/- mice (see Figure 3.2) with respect to B-cell development in bone 
marrow. The reduction of B cells in the periphery, for example in spleen, was also 
detected in p100-/-→wt chimeras (Figure 3.3 B), which was similar to that in p100-/- mice 
as well.  
 
Thus, the irradiation-resistant stromal microenvironments in wild-type recipients could 
not support the proper B-cell development when transplanted with bone marrow cells 
from p100-/- mice. These observations suggest that the B-cell development abnormality in 
mice lacking p100 arises from the hematopoietic compartment rather than the non-
hematopoietic (stromal) compartment. 
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Figure 3.3: Analysis of B-cell development in bone marrow chimeras. Lymphocytes from (A) 
BM and (B) SP were isolated from lethally irradiated mice that were transplanted with bone 
marrow cells as indicated. (A) B220 and CD19 expression in BM. (B) B220 and IgM expression 
in SP was analyzed by flow cytometry. 
 
The requirement of p100 in hematopoietic cells for proper B-cell development was 
clearly demonstrated from the above observations. It is not clear, however, whether p100 
is required within B-cell precursors or in accessory cells for their development. To 
address this point, mixed bone marrow reconstitution experiments were performed using 
C57BL/6 congenic mice.  These mice differ only in the CD45 locus which was used to 
distinguish the reconstitution of hematopoietic system from either wild-type (CD45.1+) or 
p100-/- (CD45.2+) bone marrow cells.  
 
Bone marrow cells from CD45.1+ wild-type and CD45.2+ p100-/- mice were mixed at 
equal proportions and injected into the lethally irradiated CD45.1+ wild-type recipients 
(CD45.1+ wt & CD45.2+ p100-/-→CD45.1+ wt). All the animals were checked for their 
chimeric status by PCR analysis as mentioned before. Six weeks after bone marrow 
transplantation, reconstitution of B, T, and myeloid lineages was analyzed by flow 
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cytometry. Single cell suspensions were labeled with CD45.1 or CD45.2 in combination 
with lineage markers B220 and CD19 (B cells), CD4 and CD8 (T cells), or Gr-1 
(granulocytes). Results on B lymphocytes are addressed here only. 
 
A normal profile of B220 and CD19 expression (Figure 3.4 A, left panel) was found in 
bone marrow of mixed chimeric mice (CD45.1+ wt & CD45.2+ p100-/-→CD45.1+ wt). 
Flow cytometric analysis revealed that about 60% of lymphocytes in mixed chimeric 
mice were derived from CD45.1+ wild-type bone marrow, whereas CD45.2+ p100-/- bone 
marrow contributed to 40%. Interestingly, bone marrow cells from CD45.2+ p100-/- mice 
were not able to generate B220+CD19+ cells efficiently (11.6 ± 1.3%), in spite of the co-
existence of CD45.1+ wild-type bone marrow cells (Figure 3.4 A, low-right panel). The 
majority of B220+CD19+ cells (47.0 ± 6.2%) in the mixed chimeric mice were generated 
by CD45.1+ wild-type bone marrow cells (Figure 3.4 A, up-right panel).  
 
On the other hand, B220+CD19- precursors generated by CD45.2+ p100-/- bone marrow 
were actually 2-fold increased (22.2 ± 0.3%) compared to those from CD45.1+ wild-type 
bone marrow (11.5 ± 1.4%). Nevertheless, the increased number of B220+CD19- 
precursors from CD45.2+ p100-/- bone marrow did not differentiate properly and 
generated less B220+CD19+ cells (11.6 ± 1.3%) than those from CD45.1+ wild-type bone 
marrow did (47.0 ± 6.2%). The differences among individual subpopulations generated 
by either CD45.1+ wild-type or CD45.2+ p100-/- bone marrow cells became even more 
evident when these populations (B220+CD19-, B220+CD19+, and B220-CD19-) were 
plotted on a bar chart (Figure 3.4 B).  
 
Thus, p100-/- bone marrow cells could not undergo normal B-cell development even with 
the support of wild-type bone marrow cells. p100 is required within B cells rather than in 
any other cell types for proper mainstream B-cell maturation. Taken together, these data 
indicate that the B-cell developmental abnormality in mice lacking p100 is a 
hematopoietic defect and is intrinsic to B cells.  
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Figure 3.4: Analysis of B-cell development in mixed bone marrow chimeric mice. (A) Bone 
marrow cells were isolated from lethally irradiated mice that were reconstituted with mixed bone 
marrow at a 1:1 ratio. Flow cytometric analysis was performed after staining with anti-CD45.1 or 
anti-CD45.2 together with anti-B220 and anti-CD19 antibodies. Lymphocytes were gated. (B) 
Statistics chart for the absolute numbers of B220+CD19-, B220+CD19+, and B220-CD19- cells 
generated from either CD45.1+ wild-type or CD45.2+ p100-/- bone marrow cells. 
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3.1.2  B-cell developmental defect in p100-/- mice is due to 
enhanced RelB DNA-binding activity 
The C-terminal portion of p100 precursor specifically inhibits nuclear translocation of 
RelB complexes in the alternative NF-κB activation pathway (Figure 3.5, left panel, see 
1.1.4) [17]. In p100-/- mice (targeted disruption only on the C-terminal portion of the 
nfκb2 gene, see Figure 1.3), p52 molecule can still be synthesized but p100 precursor 
cannot. A constitutive increase of κB DNA-binding activity (Figure 3.5, right panel), 
mainly comprising p52/RelB complexes, was observed in nuclear extracts from various 
lymphoid and non-lymphoid tissues of p100-/- mice, according to published data [36] and 
the current work (see Figure 3.8, lane 4). 
 
 
Figure 3.5: Schematic representation of increase κB DNA-binding activity in mice lacking 
p100. Activation of alternative NF-κB pathway leading to the nuclear translocation of p52/RelB 
heterodimers is shown in the left panel. The targeted disruption of C-terminal of p100 resulting in 
the constitutively activation of p52/RelB heterodimers is shown in the right panel. Cross in red 
indicates the deletion of C-terminal portion of p100. 
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3.1.2.1  B-cell developmental defect in p100-/- mice is rescued by deleting one 
allele of the relB gene  
RelB heterodimers bind constitutively to κB motifs in lymphoid tissues of p100-/- mice. 
One possibility is that the defective B-cell development in these animals is due to 
increased RelB function. To address this point, relB-/- mice were bred with p100-/- mice 
(Figure 3.6 A). p100-/-relB-/+ as well as p100-/-relB-/- mice were examined to investigate 
the effect of RelB activity on B-cell development. 
 
Unlike p100-/- mice, p100-/-relB-/+ mice were healthy during the four-month of 
observation. B-cell development was investigated both in bone marrow and spleen. Flow 
cytometric analysis of bone marrow cells from 3-week-old p100-/-relB-/+ mice revealed an 
increase in B220+CD19+ double-positive B cells with a mean frequency of 57.6 ± 3.2% 
(Figure 3.6 B, middle panel) compared to 4.65 ± 1.1% in p100-/- mice (Figure 3.6 B, left 
panel). The percentage of bone marrow B220+CD19+ B cells in p100-/-relB-/+ mice 
reached that in wild-type controls, 65.2 ± 1.1% (Figure 3.6 B, right panel). The 
percentages of B220+CD19- cells were comparable among p100-/-, p100-/-relB-/+, and 
wild-type mice. Similarly, normal profiles of B lymphocytes were observed in the 
periphery, such as in spleen, when B220 and IgM expressions were analyzed by flow 
cytometry (Figure 3.6 C, middle and right panels).  
 
In conclusion, when one allele of the relB gene is inactivated in p100-/- mice (p100-/-relB-
/+), the number of bone marrow B220+CD19+ B lymphocytes is completely recovered to 
that in wild-type mice. The reduction of peripheral B lymphocytes in p100-/- mice is 
rescued in p100-/-relB-/+ mice as well. Thus, the developmental arrest of B lymphocytes 
(B220+CD19- (Fr. A) to B220+CD19+ (Fr. B)) in bone marrow and the impaired B 
lymphopoiesis in periphery in p100-/- mice are rescued upon deletion of one relB allele. 
These observations support the assumption that the strength of RelB activity affects 
mainstream B-cell development. 
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Figure 3.6: B-cell development is rescued in p100-/-relB-/+ mice. (A) Schematic representation 
of the breeding strategy for investigating the effects of RelB activity on B-cell development. B-
cell development was examined in (B) BM and (C) SP by flow cytometric analysis from mutant 
and wild-type mice as indicated. Lymphocytes were gated. Numbers indicate mean values (%) ± 
SD from four mice. 
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3.1.2.2  B-cell developmental defect in p100-/- mice can not be rescued by 
complete deletion of the relB gene 
When two alleles of the relB gene were completely deleted in p100-/- mice (p100-/-relB-/-), 
flow cytometric analysis revealed a slight reduction of bone marrow B220+CD19+ cells in 
3-week-old double mutant mice compared to that in wild-type mice (Figure 3.7 A, left 
and right panels). Moreover, only a total of 8% B220+ cells were detected in spleen. Both 
B220+IgM- and B220+IgM+ B-cell populations were markedly reduced in p100-/-relB-/-
mice (Figure 3.7 B). These phenotypes in B lymphopoiesis either in bone marrow or in 
spleen were very similar to what had been reported in relB-/- mice (Figure 3.7 A and B, 
middle panels) due to the increased apoptosis and the abnormal mature B-cell 
proliferation [106].  
 
Actually, p100-/-relB-/- mice, at around 4-week of age, started manifesting other similar 
phenotypes to relB-/- mice; for example, splenomegaly, and lack of PP as well as LN. 
Thus, the complete inactivation of the relB gene could not rescue the phenotype of p100-/- 
mice; to the contrary, these mice develop the phenotype of relB-/- mice. 
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Figure 3.7: Failure to rescue B-cell developmental defect upon complete deletion of the relB 
gene in p100-/-mice. (A) BM and (B) SP cells were isolated from 3-week-old double mutant (left 
panels), relB-/- (middle panels), and wild-type mice (right panels) for flow cytometric analysis. 
(A) B220 and CD19 expression in BM, (B) B220 and IgM expression in SP were examined. 
 
3.1.2.3  RelB activity affects B-cell development  
B-cell development is arrested in a cell-intrinsic manner in p100-/- mice. Interestingly, 
normal B-cell development is found in p100-/-relB-/+ mice.  In order to understand the 
molecular mechanisms in the above observations, the κB DNA-binding activity in 
nuclear extracts of mutant and wild-type mice was examined by the electrophoretic 
mobility shift assay (EMSA). Due to technical difficulties to perform EMSA successfully 
in sorted B220+CD19- B cells, this experiment was done with thymocyte nuclear extracts.  
 
In wild-type mice, RelB DNA-binding activity was identified by anti-RelB antibody 
challenge, which was significantly enhanced in p100-/- mice (Figure 3.8; compare 
supershifted bands in lane 2 and 4). When one allele of the relB gene was deleted in 
p100-/- mice, the elevated RelB DNA-binding activity was restored to more or less same 
levels as that in wild-type control (compare supershifted bands in lane 2, 4, and 6). As 
expected, when two alleles of the relB gene were deleted, the RelB DNA activity could 
not be detected at all (lane 8).  
 
In conclusion, p100-/- mice lacking RelB inhibitor exhibit constitutively increased RelB 
DNA-binding activity corresponding to B-cell developmental defect. p100-/-relB-/+ mice, 
lacking one allele of the relB gene in p100-/- mice, exhibit rescued RelB DNA-binding 
activity (wild-type levels), correlated with the rescue in the B-cell developmental defect. 
These observations strongly indicate that the strength of RelB activity plays a crucial role 
in B lymphopoiesis. High levels of RelB activity (p100-/-) interfere with the B-cell 
development at the early stage; normal (medium) levels of RelB activity (p100-/-relB-/+) 
favor this process; absence of RelB activity (p100-/-relB-/-) affects mainly B-cell 
activation and survival rather than mainstream B-cell development.  
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Figure 3.8: Electrophoretic mobility shift assay (EMSA). Thymocyte nuclear extracts from 
wild-type, p100-/-, p100-/-relB-/+, and p100-/-relB-/- mice were prepared and analyzed for κB DNA-
binding activity by EMSA using Igκ probe. α-RelB: α-RelB mAb; p.i.: preimmune treatment. 
RelB supershift is indicated by arrow. Integrity of the extracts was analyzed by EMSA using Oct-
1 probe. The blue-color rectangles indicate the supershifted RelB bands from either wild-type 
(left) or p100-/-relB-/+ (right) mice.  
 
3.1.2.4  B-cell developmental defect in p100-/- mice can not be rescued by 
deletion of the nfκb1 gene  
Nuclear extracts of various lymphoid and non-lymphoid tissues from p100-/- mice 
exhibits a significant increase of κB DNA-binding activity mainly consisting p52/RelB 
heterodimers. To rule out the opportunity that the increased p50 complexes DNA-binding 
activity is another reason for the impaired B-cell development, the nfκb1 gene was 
deleted in p100-/- mice and the B-cell development was analyzed by flow cytometry.  
 
Neither p100-/-nfκb1-/- nor p100-/-nfκb1-/+ mice could be distinguished from age-matched 
p100-/- mice: they were severely runted since 14–16-day old, approximately half to one 
third smaller than wild-type controls, and did not survive longer than 21 days after birth.  
 
It is known that NF-κB1/p50 is not involved in the mainstream B-cell development [21].  
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Flow cytometric analysis showed that the percentages of both B220+CD19+ and 
B220+CD19- cell populations were comparable between nfκb1-/- and wild-type mice 
(Figure 3.9, upper panels). However, B220+CD19+ cells were dramatically reduced in 
both p100-/-nfκb1-/+ and p100-/-nfκb1-/- mice (Figure 3.9, lower panels), similar to that in 
p100-/- mice. Moreover, B220+CD19- cells were reduced to some extent in these mice, 
compared to p100-/-, nfκb1-/-, and wild-type animals.  
 
These data show that deleting either one allele or two alleles of the nfκb1 gene in p100-/- 
mice could not rescue the B-cell developmental defects in p100-/- mice as indicated by the 
massive loss of B220+CD19+ cells in bone marrow. Thus, DNA-binding activity of p50 
complexes does not contribute to the impaired B-cell development in p100-/- mice. In 
addition, due to the mild but discernable reduction of B220+CD19- cells in p100-/-nfκb1-/+ 
and p100-/-nfκb1-/- mice, the B-cell developmental defect in these animals could be even 
more severe and complex than that in p100-/- mice.  
 
Figure 3.9: p50 does not contribute to B-cell developmental defect in p100-/- mice. Bone 
marrow cells were isolated from wild-type, nfκb1-/-, p100-/-, p100-/-nfκb1-/+, and p100-/-nfκb1-/- 
mice. Lymphocytes were gated for flow cytometric analysis after staining with anti-B220 and 
anti-CD19 antibodies. 
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3.1.3  The expression of certain B-lineage commitment genes is 
affected by enhanced RelB DNA-binding activity in p100-/- 
mice  
The transcription factor Pax5 is crucial in maintaining B-lymphocyte commitment. In 
Pax5-/- bone marrow, B220+CD43+CD19+ cells are absent [123]. In p100-/- mice, B 
lymphopoiesis is arrested at a similar stage (from Fr. A to Fr. B) as in Pax5-/- mice 
(Figure 3.10 A). Thus, one possibility is that p100 regulates the expression of Pax5.  
 
To address this point, Pax5 mRNA expression was analyzed using real-time PCR in the 
sorted B220+CD19- cell population from control and mutant mice. Cells were sorted 
using MACS depletion combined with positive selection methods and 95% purity was 
achieved in these experiments. Interestingly, almost no Pax5 expression was detected in 
the mutant mice in contrast to wild-type controls (Figure 3.10 B).  
 
Another two transcription factors E2A and EBF are also required for the proper 
development of early B progenitors and for the cooperative activation of the B-lymphoid 
gene expression program at the onset of B-cell development. In E2A-/- or EBF-/- bone 
marrow, B220+CD43+CD19- cells are greatly reduced, suggesting that the developmental 
arrests in these mice take place at Fr. A1 to Fr. A2 stage (Figure 3.10 A). E2A and EBF 
mRNA expressions were also examined by real-time PCR. E2A expression was 
comparable to wild-type controls. EBF mRNA levels were 5-fold reduced in mutant mice 
(Figure 3.10 B). These results suggest that p100 regulates the expression of certain B-
lineage transcription factors, such as Pax5 and EBF.  
 
A downregulated expression pattern of B-lineage transcription factors Pax5 and EBF was 
found in p100-/- mice, explaining the phenotype in B-cell development. It is known from 
the study that, in p100-/- mice, B-cell development is arrested due to the constitutively 
increased RelB DNA-binding activity. When one allele of the relB gene is deleted in 
p100-/- mice, the elevated RelB DNA-binding activity recovers to wild-type levels, 
correlated with the rescued B-cell development. Interestingly, the expression levels of 
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Pax5 and EBF were also rescued to wild-type levels (data not shown) when one allele of 
the relB gene was deleted in p100-/- mice, indicating that the expression of Pax5 and EBF 
was affected by the strength of RelB DNA-binding activity as well. Thus, the 
downregulation of Pax5 and EBF in p100-/- mice is likely due to the enhanced RelB 
DNA-binding activity. 
 
 
Figure 3.10: p100 regulation of the expression of B-lineage transcription factors. (A) 
Schematic figure of the developmental stages at which the B-lymphocyte differentiation was 
arrested in E2A-/-, EBF-/-, Pax5-/-, and p100-/- mice. Vertical bars indicate the development blocks 
at different stages. (B) Real-time PCR of B-lineage transcription factors. B220+CD19- cells were 
sorted from bone marrow of 3-week-old wild-type and p100-/- mice using MACS. Real-time PCR 
was performed to examine the expression of B-lineage transcription factors. Data represent two 
independent experiments. 
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B-cell associated genes such as CD19, mb1 (Igα), and BLNK also showed the attenuated 
mRNA levels in sorted B220+CD19- bone marrow cells from 3-week-old p100-/- mice. 
The expression of T- and myeloid-lineage specific genes, such as Notch1, M-CSFR, and 
MPO was comparable to wild-type controls (Figure 3.11), corresponding to the intact 
development of T cells and myeloid cells in p100-/- mice.  
 
It is known that in B-cell development, Pax5 activates the B-cell associated genes. 
Moreover, Pax5 represses genes such as M-CSFR and MPO as well as Notch1, which are 
involved in the development of other lineages. This dual function of Pax5 leads to the 
consolidation of the B-lymphoid gene expression program. Thus, it is likely that the 
disturbed lineage-associated gene expression pattern observed in p100-/- mice is due to 
the marked reduction of Pax5 expression [56].  
 
 
Figure 3.11: The expression of lineage-associated genes in mice lacking p100. B220+CD19- 
cells were sorted from bone marrow of 3-week-old wild-type or p100-/- mice using MACS. Real-
time PCR was performed to examine the mRNA expression of different lineage-associated genes. 
Data represent two independent experiments.  
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3.1.4  B-cell developmental defect in p100-/- mice is not due to 
increased number of myeloid cells 
3.1.4.1  Myeloid hyperplasia in p100-/- mice 
In addition to B-lymphocyte developmental abnormality in bone marrow which results in 
reduced number of B lymphocytes in the periphery of p100-/- mice, myeloid hyperplasia 
without clear evidence of infection was observed in bone marrow, spleen, peripheral 
blood, and other lymphoid organs of these mice (Figure 3.12). Mac-1 (CD11b) and Gr-1 
were used as myeloid lineage markers for flow cytometric analysis.  
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Figure 3.12: Increased number of myeloid cells in p100-/- mice. Single cell suspensions were 
prepared from (A) bone marrow (BM), (B) spleen (SP), and (C) peripheral blood (PBL). Gr-1 and 
Mac-1 expressions were analyzed by flow cytometry in 3-week-old wild-type (left panels) and 
mutant mice (right panels).  
 
3.1.4.2  Myeloid hyperplasia in p100-/- mice is not due to the increased myeloid 
precursors  
The myeloid hyperplasia in p100-/- mice could be due to an increased frequency of 
myeloid precursor cells. To investigate this possibility, colony formation assays were 
performed using different FACS-sorted bone marrow cells (Table 3-1) from either wild-
type or mutant chimeras (in collaboration with Dr. Terszowski, Ulm).  
FACS-sorted cells Cell surface markers 
CMP+ Lin-/Thy-1.1-/IL-7R-/c-Kithigh/Sca-1-/CD34+/FcγRlow 
GMP Lin-/Thy-1.1-/IL-7R-/c-Kithigh/Sca-1-/CD34high/FcγRhigh 
Table 3-1: The expression patterns of cell surface markers in different FACS-sorted bone 
marrow cell populations. CMP: common myeloid progenitors, GMP: granulocyte/macrophage 
progenitors. 
 
In general, CMP+ cells give rise to myeloid, erythroid, and megakaryocyte colonies 
including mixed colonies (Mix).  GMP cells only give rise to colonies composed of 
macrophages and/or granulocytes. 
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The results of colony formation assays are summarized in Table 3-2. Numbers indicate 
the colonies obtained after plating different sorted bone marrow cell populations in 
methylcellulose supplemented with EPO (erythropoietin), TPO (thrombopoietin), IL-3, 
SCF, M-CSF, and GM-CSF.  
 
CMP+ cells either from wild-type or p100-/- chimeras generated erythrocytes (BFU-E), 
myeloid cells (CFU-GM), megakaryocytes (CFU-Meg), and mixed cell colonies (Mix). 
Moreover, similar numbers in CFU-GM, Mix, and CFU-GM&CFU-Meg colonies 
generated from CMP+ cells were found in both wild-type and mutant animals (Table 3.2, 
shaded with blue color). GMP cells only generated myeloid cells (CFU-GM).  Same 
numbers of CFU-GM colonies were obtained in both wild-type and mutant animals 
(Table 3.2, shaded with pink color).  
wild-type 
chimeras BFU-E 
CFU-
GM 
CFU-
Meg Mix
BFU-E 
CFU-GM
BFU-E 
CFU-Meg 
CFU-GM 
CFU-Meg
10 87 2 1 3 1 2 CMP+ 
7 95 3 0 2 1 3 
0 76 0 0 0 0 0 GMP 
0 79 0 0 0 0 0 
p100-/- 
chimeras  
6 105 1 1 9 15 4 CMP+ 
7 103 0 0 11 16 5 
0 78 0 0 0 0 0 GMP 
0 81 0 0 0 0 0 
Table 3-2: Colony formation assays. Individual FACS-sorted BM cell populations (CMP+ and 
GMP) from wild-type and mutant chimeras were cultured in methylcellulose. The numbers from 
two independent experiments are presented in two rows (upper and lower) for every assay. BFU-
E: erythroid burst-forming units; CFU-GM: colony forming unit-granulocyte macrophage; CFU-
Meg: colony forming unit-megakaryocyte. 
 
Taken together, there was no statistically significant difference in the myeloid-colony 
formation, indicating that the number of myeloid precursor cells in p100-/- chimeras bone 
marrow was comparable to that in wild-type chimeras. Thus, accumulation of myeloid 
cells observed in different lymphoid organs in mice lacking p100 is not due to an 
increased myeloid-precursor frequency.  
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3.1.4.3  B-cell developmental defect in p100-/- mice can not be rescued upon 
depletion of myeloid cells  
The myeloid hyperplasia in p100-/- mice is evident as indicated by the above observations. 
It is possible that the defective B-cell development in p100-/- mice is caused by the 
massively increased myeloid cells. To examine this possibility, myeloid cells were 
depleted using anti-granulocyte monoclonal antibodies (mAb) RB6-8C5 in mutant 
animals. In this case, B-cell development in mice lacking p100 can be investigated 
without the influence of a large number of myeloid cells. RB6-8C5 mAb reacts with a 
common epitope on Ly-6G and Ly-6C, known as the myeloid differentiation antigen Gr-
1 [124].  
 
The p100-/- mice usually survive no more than 21 days, hampering the feasibility to 
perform a myeloid-cell depletion experiment. Therefore, bone marrow chimeras were 
generated (see 3.1.1.3, Figure 3.3) and used for this experiment because they can survive 
longer.  
 
p100-/-→wt bone marrow chimeras received 150 µg RB6-8C5 mAb intraperitoneally 
(i.p.) and another 150 µg two days later, resulting in neutropenia for 3 to 4 days [125]. 
p100-/-→wt chimeras without injection and wt→wt chimeras that received PBS i.p. were 
used as controls. Mac-1 and CD19 expression in peripheral blood was analyzed by flow 
cytometry every other day to monitor the fluctuation of myeloid and B-lymphoid cells 
after injections.  
 
Only 9.54% Mac-1+ cells (Figure 3.13 A, right panel) in peripheral blood were detected 
in p100-/-→wt chimeras three days after RB6-8C5 mAb injections (one day after the 
second injection). Mac-1+ cells in these animals were clearly reduced compared to those 
in p100-/-→wt chimeras without injection (51.16%, Figure 3.13 A, middle panel), 
indicating successful myeloid cell depletion. However, depletion of myeloid cells did not 
lead to an increase of B lymphocytes in peripheral blood; only 23% CD19+ B cells were 
detected (Figure 3.13 B, right panel). This percentage was close to 17.64% observed in 
p100-/-→wt chimeras without injection (Figure 3.13 B, middle panel) and was 3-fold 
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reduced compared to 71% CD19+ B cells in wt→wt chimeras that received PBS 
injections (Figure 3.13 B, left panel). These phenomena lasted six days after injections. 
On the seventh day, the percentage of myeloid cells in p100-/-→wt chimeras that received 
RB6-8C5 mAb injections went back to 65.45% (Figure 3.13 A, lower-right panel).  
 
Despite the fluctuation in the number of PBL myeloid cells in p100-/-→wt chimeras that 
received RB6-8C5 mAb injections, the number of PBL CD19+ B-lymphoid cells of these 
animals stayed low and unchanged for seven days. These results become much clear 
when plotted on a line chart (Figure 3.13 C). In conclusion, it is unlikely that the 
defective B-cell development in mice lacking p100 is caused by increased number of 
myeloid cells. The reason for the increased myeloid cells in p100-/- mice is not clear; 
colony formation assay has excluded the possibility of the increased frequency of 
myeloid precursors. 
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Figure 3.13: Analysis of the correlation between B-cell developmental defect and myeloid 
hyperplasia in mice lacking p100. Depletion of myeloid cells was preformed using anti-
granulocyte monoclonal antibody RB6-8C5 injections i.p.. Peripheral blood was analyzed every 
other day after the antibodies injections. (A) Flow cytometric analysis after staining with Mac-1 
antibody showed the fluctuation of myeloid cells from wt→wt that received PBS (left panels), 
p100-/-→wt without injection (middle panels), and p100-/-→wt chimeras that received RB6-8C5 
antibody injections (right panels). (B) Flow cytometric analysis after staining with CD19 
antibody. Lymphocytes were gated for this analysis. (C) Line charts for the fluctuation in myeloid 
cells and the percentage of CD19+ cells in PBL before and after injections. Blue lines indicate 
wt→wt that received PBS, pink line p100-/-→wt chimeras that received RB6-8C5 injections. 
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3.1.5  The lympho-myeloid potential of p100-/- pro-B cells  
3.1.5.1  p100-/- pro-B cells undergo transition to myeloid lineage 
It has been shown that Pax5-/- pro-B cells can be cultured on the stromal cells ex vivo in 
the presence of IL-7. These cells can be induced to differentiate into various cell types 
including nature killer cells, dendritic cells, macrophages, osteoclasts, and granulocytes 
upon withdrawal of IL-7 and addition of appropriate cytokines [126]. A similar 
phenotype between p100-/- and Pax5-/- mice with respect to early B-cell development (see 
Figure 3.10 A) has been found in this study, raising the possibility that p100-/- pro-B cells 
may also have the lympho-myeloid potential similar to the plasticity of Pax5-/- pro-B cells 
in the differentiation into other lineages (see Figure 1.6). 
 
To address this possibility, B220+CD19- bone marrow cells from 3-week-old wild-type 
and mutant mice were sorted using MACS to obtain a purity of ≥ 95%. These cells were 
then cultured on ST2 stromal cells in the presence of either IL-7 or M-CSF. After 10 
days, the suspension cells were harvested and analyzed for CD19 and Mac-1 expression 
by flow cytometry.  
 
In wild-type cultures, almost all B220+CD19- pro-B cells differentiated along B-cell 
lineage in the presence of IL-7 (94% CD19+ cells, Figure 3.14, upper-left panel) while 
nearly half of them lost B-lineage specific markers in the presence of M-CSF (63% 
CD19+ cells and 27% Mac-1+ cells, Figure 3.14, upper-right panel). After 10 days in IL-
7 cultures, only 28% p100-/- pro-B cells differentiated into CD19+ cells while 60% pro-B 
cells lost their B-lymphocyte potential and differentiated into Mac-1+ cells (Figure 3.14, 
lower-left panel). When p100-/- pro-B cells were cultured in the presence of M-CSF, the 
percentage of cells, which underwent differentiation to myeloid cells, was not further 
enhanced (62%). However, the biphenotypic cells, expressing low levels of both CD19 
and Mac-1 in this culture, were detected in greatly increased numbers (Figure 3.14, 
lower-right panel) and merely 7% CD19+ cells were found.  
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Figure 3.14: p100-/- pro-B cells transit to myeloid cells ex vivo. Sorted B220+CD19- cells from 
3-week-old wild-type and mutant mice were cultured on ST2 stromal cells with IL-7 or M-CSF. 
Flow cytometric analysis was performed for CD19 and Mac-1 expression after 10 days of culture. 
 
Taken together, p100-/- pro-B cells have a similar potential to Pax5-/- pro-B cells in terms 
of lympho-myeloid transdifferentiation. Interestingly, p100-/- pro-B cells can even 
transdifferentiate into myeloid cells in the culture of IL-7, which supports B-lymphocyte 
proliferation and differentiation. In addition, p100-/- pro-B cells do produce less CD19+ B 
lymphocytes than wild-type pro-B cells (28% vs. 94%) when they are cultured on the 
stromal cells ex vivo, further supporting that B-cell developmental defect in p100-/- mice 
is cell-intrinsic. It is assumed, then, that the evident myeloid hyperplasia without 
evidences of inflammation in different lymphoid organs of p100-/- mice is arise from the 
transdifferentiation of B-lineage progenitors to myeloid cells. 
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3.1.5.2  Transition of p100-/- pro-B cells to the myeloid lineage correlates with 
increased C/EBPα expression 
p100-/- pro-B cells can transit to myeloid cells as indicated by the above observations. 
The molecular mechanism in this process is unknown. Recent report [91] shows that the 
transfection of C/EBPα can reprogram wild-type mature B cells to transdifferentiate into 
myeloid cells. This process is accompanied by the downregulation of Pax5 and intact 
endogenous PU.1 activity (see 1.2.1.5). C/EBPα is expressed in myeloid progenitors and 
upregulated during granulocyte development. PU.1 belongs to the Ets transcription 
factors family and is expressed in hematopoietic stem cells and all differentiated cells 
except erythroblasts, megakaryocytes, and T cells. Low PU.1 expression favors B-cell 
development while high PU.1 level promotes macrophage differentiation.  
 
To determine whether C/EBPα and/or PU.1 play a role in the process of transition of 
p100-/- pro-B cells to myeloid cells, mRNA levels in sorted B220+CD19- bone marrow 
cells were checked by real-time PCR. Surprisingly, the expression of C/EBPα mRNA 
levels was increased 5-fold, whereas PU.1 expression remained unchanged (Figure 
3.15). Thus, it is most likely that the plasticity of p100-/- pro-B cells in the differentiation 
to myeloid cells is due to the upregulation of C/EBPα expression. 
 
Figure 3.15: Increased expression of C/EBPα mRNA in p100-/- pro-B cells. B220+CD19- bone 
marrow cells were sorted from 3-week-old wild-type and p100-/- mice. Real-time PCR was 
performed using cDNA prepared from sorted B220+CD19- cells. Data represent two independent 
experiments. 
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3.1.6  Other B-cell subpopulations affected by p100 deficiency  
After successful immunoglobulin gene rearrangement in bone marrow, immature B cells 
further migrate to spleen. Upon completing maturation from the T1 stage to the T2 stage, 
the majority of these cells enter the follicular subset, which constitutes the bulk of the 
peripheral B-cell pool and populates B-cell follicles in secondary lymphoid organs. 
Alternatively, some of these newly formed (NF) cells can be recruited to the far smaller 
MZ B or B1 B subset (see Figure 1.4).  
 
3.1.6.1  Altered B-cell subpopulations in p100-/- spleen 
The splenic IgMhiIgD- population includes T1 B cells (CD21-CD23-) and MZ B cells 
(CD21hiCD23-). T2 B cells are IgMhiIgDhi whereas FO B cells are IgMloIgDhi (Table 3-
3).  
 
Table 3-3: Phenotypic description and tissue distribution of immature, T1, T2, mature 
(FO), and MZ B cells. Expression of the indicated cell surface markers is given as negative (-), 
low (+), intermediate (++), and high (+++). The location where the various cell types are found is 
also indicated. BM: bone marrow, B: blood, S: spleen, and LN: lymph nodes. IMM: immature. 
(Adapted from [127]) 
 
A reduction in IgMhiIgDhi (T2 B) and IgMhiIgD- (T1 B and MZ B) populations was 
observed in spleen from 3-week-old p100-/- mice (Figure 3.16). However, the percentage 
of mature recirculating FO B cells (IgMloIgDhi) was comparable to that in wild-type mice.  
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Figure 3.16: p100-deficiency alters T1, T2, MZ, and FO B-cell subsets. The expression of cell 
surface markers, IgM and IgD was examined to discriminate different B-cell subsets in spleen by 
flow cytometric analysis from 3-week-old wild-type (left panel) and p100-/- mice (right panel). 
Lymphocytes were gated for the analysis. 
 
3.1.6.2  Accumulation of MZ B cells in p100-/- mice 
MZ B cells are specifically located in the region outside of the marginal sinuses of 
lymphoid follicles in spleen and function as a first line of defense to blood-born 
pathogens. This specialized B-cell population is characterized by high surface expression 
of CD21/CD35 and negative expression CD23, whereas follicular B cells are 
CD21/CD35intCD23int (see Table 3-3).  
 
Flow cytometric analysis of splenocytes from 3-week-old p100-/- mice revealed a 
substantial increase of MZ B cells (p100-/-, 7.04% vs. wild-type 1.72%) and a decrease of 
follicular B cells (Figure 3.17 A and C). In the CD23- population, the increase of MZ B 
cells (CD21hiIgMhi) was also detected upon CD21 and IgM staining, 7.08% in p100-/- vs. 
1.53% in wild-type mice. The percentage of the T1 B-cell population (CD21-IgMhi) was 
moderately decreased from 15.53% in wild-type to 11.07% in p100-/- mice (Figure 3.17 
B, left panels). In the CD23+ population, a ~2-fold reduction in the T2 B-cell population 
(CD21hiIgMhi) was detected in p100-/- mice (Figure 3.17 B, right panels). This result is 
consistent with the previous observations when IgM and IgD were used as cell surface 
markers for detection of T2 B cells (see Figure 3.16). 
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Figure 3.17: Increase of MZ B cells in p100-/- mice. (A) Flow cytometric analysis of 
splenocytes from 3-week-old wild-type (upper panels) and p100-/- mice (lower panels) stained 
with CD23 and CD21 antibodies. Lymphocytes were gated for the analysis. (B) Lymphocytes 
were gated as CD23- (left panels) or CD23+ population (right panels) for further analysis of CD21 
and IgM expression. (C) The percentage of T1, T2, FO, and MZ B-cell populations in wild-type 
and p100-/- mice. 
 
Thus, there is an altered distribution of B cells in p100-/- spleen. The transitional 
compartment, which constitutes T1 B and T2 B cells, is decreased. However, the mature 
compartment, which constitutes MZ B and FO B cells, is enlarged and unaffected 
respectively. The reduction in T1 B and T2 B subsets actually leads to the 2–3-fold 
reduction of total B lymphocytes in spleen (see Figure 3.1).  
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3.1.6.3  Accumulation of MZ B cells in p100-/- mice is cell-intrinsic 
The accumulation of marginal zone B cells in p100-/- spleen could result either from a B-
cell autonomous defect or from a defect in the stromal microenvironment. To test this, 
competitive bone marrow reconstitution experiments were performed as previously 
described (see 3.1.1.3). In brief, bone marrow cells from CD45.1+ wild-type and CD45.2+ 
p100-/- mice were mixed at equal proportions and injected into lethally irradiated 
CD45.1+ wild-type recipients. Six weeks after bone marrow transplantation, the 
development of MZ B cells was analyzed by flow cytometry for the expression of CD21 
and CD23 together with CD45.1 or CD45.2 in spleen of chimeric mice.  
 
A normal frequency of CD21hiCD23- MZ B cells (3.99%, Figure 3.18, left panel) was 
found in spleen of mixed chimeric mice (CD45.1+ wt & CD45.2+ p100-/-→CD45.1+ wt). 
Interestingly, CD45.2+ p100-/- bone marrow cells had a priority to generate MZ B cells 
despite the co-existence of CD45.1+ wild-type bone marrow cells, 7.35% compared to 
2.2% from CD45.1+ wild-type bone marrow cells (Figure 3.18, middle and right panels).  
 
Figure 3.18: Analysis of marginal zone B-cell development in mixed bone marrow chimeric 
mice. Splenocytes were isolated from lethally irradiated mice that were reconstituted with bone 
marrow cells mixed at a 1:1 ratio. Flow cytometric analysis was performed after staining with 
anti-CD45.1 or anti-CD45.2 together with anti-CD21 and anti-CD23 antibodies.  
 
Thus, p100-/- bone marrow cells are not able to undergo normal MZ B-cell development 
even with the support of wild-type bone marrow cells and stromal environment. p100 
within B cells rather than in any other cell types is necessary for proper MZ B-cell 
development. Taken together, these data suggest that the MZ B-cell developmental defect 
in mice lacking p100 is a hematopoietic defect and is intrinsic to B cells.  
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3.1.6.4  Partial rescue of MZ B-cell accumulation by deleting one allele of the 
relB 
It is demonstrated from above studies that deleting one allele of the relB gene in p100-/- 
mice, which reduced the increased RelB DNA-binding activity to wild-type levels, could 
rescue the phenotypes in p100-/- mice regarding to the early mainstream B-cell 
developmental defect (see 3.1.2). It is likely that MZ B-cell development could also be 
affected by RelB DNA-binding activity.  
 
Flow cytometric analysis of splenocytes from 3-week-old p100-/-relB-/+ mice revealed a 
moderate increase of CD21hiCD23- MZ B cells compared to that in wild-type mice (3.1% 
vs. 2.04%, Figure 3.19 A, upper and middle panels). The follicular B-cell compartment 
is unaffected. Almost no MZ B cells were found in 3-week-old p100-/-relB-/- mice (0.2%, 
Figure 3.19 A, lower panel), which was similar to that in relB-/- mice [107]. 
 
In the CD23- population, the increase of MZ B cells (CD21+IgM+) was much clear in 
p100-/-relB-/+, 4.38% vs. 1.67% in wild-type mice. This percentage of MZ B cells is lower 
than that in p100-/- (7.08%, Figure 3.17 B) but higher than that in wild-type mice. This 
increment in MZ B cells was absent when two alleles of the relB gene were deleted in 
p100-/- mice (Figure 3.19 B and C).  
 
A constitutively increased RelB DNA-binding activity and an enlarged MZ B-cell 
compartment are detected in p100-/- mice lacking RelB inhibitor. When one allele of the 
relB is inactivated in p100-/- mice (p100-/-relB-/+), the RelB DNA-binding activity restores 
to wild-type levels (see Figure 3.8), correlated with the rescue in mainstream B-cell 
development. However, unlike the rescue in the mainstream B-cell development, only a 
partial rescue is found in the MZ B-cell development in p100-/-relB-/+ mice. When the 
relB gene is completely inactivated in p100-/- mice (p100-/-relB-/-), almost no MZ B cells 
are present. These observations suggest that the strength of the RelB activity also plays 
an important role in the generation of MZ B cells. High levels of the RelB activity (p100-
/-) favor MZ B-cell generation; the lack of the RelB activity (p100-/-relB-/-) abolishes MZ 
B-cell generation. 
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Figure 3.19: RelB activity affects the development of MZ B cells. (A) Flow cytometric 
analysis of splenocytes from 3-week-old wild-type, p100-/-relB-/+, and p100-/-relB-/- mice for the 
expression of CD23 and CD21 expression. Lymphocytes were gated for the analysis. (B) 
Lymphocytes were gated as CD23- population or CD23+ population when analyzed for the 
expression of CD21 and IgM. (C) The percentage of T1, T2, and MZ B-cell populations. 
 
Collectively, in addition to that RelB functions mainly in the activation of mature B cells 
from previous studies, the work here demonstrates, for the first time, that the strength of 
RelB activity does affect the development of mainstream B-cell at early stage in bone 
marrow as well as the development of other B-cell subsets such as MZ B cells in a cell-
intrinsic manner. Thus, p100, the potent inhibitor of RelB, functions crucially in B 
lymphopoiesis at different stages (see Figure 4.1).  
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3.2         Generation of mouse models to dissect the role of 
individual NF-κB pathways in secondary lymphoid 
organogenesis 
The LTβR signaling pathway is involved in the development of secondary lymphoid 
organs such as lymph nodes (LNs) and Peyer’s patches (PPs) as well as the lymphoid 
compartment in spleen. When triggered by membrane-bound LTα1β2 heterotrimers, two 
NF-κB signaling pathways are activated in mouse fibroblast system [12-15]. The 
importance of alternative NF-κB signaling pathway, activating p52/RelB heterodimers in 
secondary lymphoid organogenesis, is illustrated by similar phenotypes in different 
mutant mice (see Table 1-4). The classical NF-κB signaling pathway, activating mainly 
p50/RelA heterodimers, contributes to secondary lymphoid organogenesis as well since 
mice deficiency in both RelA and TNFR-1 lack LNs and PPs.  
 
However, the precise in vivo contribution of RelB and RelA downstream of LTβR 
signaling for secondary lymphoid organogenesis is unclear. The work here will focus on 
establishing an in vivo model system, in which the individual contribution of alternative 
(RelB) and classical (RelA) complexes downstream of LTβR signaling can be analyzed 
with a focus on secondary lymphoid organ development.  
 
Toward this goal, one approach is to generate transgenic mouse lines, in which the 
activation of RelB or RelA complexes by LTβR can be selectively blocked. To achieve 
this, transgenic mouse lines that express the Cre recombinase under the control of LTβR 
regulatory elements will be generated. These mice will then be crossed with mice 
carrying conditional (floxed) relB or relA alleles to selectively block RelB or RelA in 
LTβR-expressing cells (Figure 3.20). This strategy will provide a significant mice model 
system for studying the individual contribution of each NF-κB pathway to LTβR-
dependent processes on the organic level. 
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Figure 3.20: Schematic figure of the relB and relA gene targeting in LTβR-expressing cells. 
Mice with a floxed relB or relA allele will be generated by homologous recombination in murine 
embryonic stem (ES) cells and then crossed to mice in which the Cre recombinase is expressed 
under the control of the LTβR regulatory elements. In the resulting relBltbr-cre and relAltbr-cre mice, 
the expression of RelB or RelA will be disrupted specifically in LTβR-expressing cells. 
 
In short, three mouse strains should be established for further analysis including mice 
harboring floxed relB (relBflox/flox) or relA alleles (relAflox/flox) and one mouse strain with 
Cre recombinase activity in LTβR-expressing cells. The relAflox/flox mice have already 
been generated in the lab of Dr. Roland Schmid (Munich) and are currently available in 
our lab. Thus, it is necessary to generate relBflox/flox mice and mice expressing Cre 
recombinase under the control of LTβR regulatory elements.  
 
The principal procedures to generate knockout mice and to further generate tissue-
specific (conditional) knockout mice are illustrated in Figure 3.21. 
 
 
 
 
 83
                                                                                                                                    Results 
 
 
Figure 3.21: Summary of experimental procedures for generating tissue-specific knockout 
mice. A modified version of the gene of interest (targeting vector) is introduced into ES cells. 
Only a few rare ES cells will have their corresponding normal gene replaced by the modified 
gene through a homologous recombination (HR) event. These altered ES cells are then injected 
into a very early mouse embryo (blastocyst). These cells will be incorporated into the growing 
embryo. A mouse produced by such an embryo will contain some somatic cells that carry the 
modified gene. Some of these mice may have germline cells that contain the modified gene. 
When bred with a wild-type mouse, some of progenies may contain the modified gene in all of 
their cells. When homozygous mouse is crossed with cre-transgenic mouse, the target gene of 
interest will be specifically mutated in certain tissues. 
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3.2.1  Generation of relBflox/flox mice 
3.2.1.1  Construction of the targeting vector pRelBXS11.2-LLTNL 
Homologous sequences in the targeting vector were amplified by PCR using 
proofreading eLONGase enzyme mix (a mixture of Taq mixed and Pyrococcus species 
GB-D thermostable DNA polymerases, Invitrogen GmbH) from plasmid pRelB-XS11.2 
[25], which contains relB genomic DNA, spanning intron III to exon VII. The 
homologous sequences of a length of 11.2 kb were divided into a 7.6 kb long arm 
(XB6.85 and BA773, Figure 3.22 A, panel 4)) and a 3.6 kb short arm (AS3.6, Figure 
3.22 A, panel 1)).  
 
The 4 kb long LTNL cassette, containing the neo and the thymidine kinase (HSVtk) 
selection marker genes, is flanked by the loxP sites. This combination pattern of the neo 
and the HSVtk genes allows negative selection using ganciclovir after transient Cre 
transfection in homologously recombined ES clones. However, only the positive 
selection using G418 can be performed after transfection of this targeting vector.  
 
LTNL cassette was placed into intron IV of the relB gene. Oligodeoxynucleotides 
encoding a single loxP sequences were inserted into intron III of the relB gene (Figure 
3.22 A, panel 3)). Exon IV will be flanked by two loxP sites in homolougous 
recombination allele (see Figure 3.23 A) and mutated in relBltbr-tg mice. Exon IV encodes 
the beginning of the Rel homology domain (RHD) of RelB. In relB-/- mice, exon IV is 
replaced by PGK-neo cassette [25] . The presence of three loxP sites in the same 
orientation was confirmed by sequencing. The cloning procedures, leading to the final 
construction of the 18.2 kb targeting vector pRelBXS11.2-LLTNL, are described in detail 
in Figure 3.22. 
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Figure 3.22: Generation of the targeting vector pRelBXS11.2-LLTNL. (A) The cloning 
procedures were separated into four steps as listed in panels 1) - 4). AS3.6 fragment was the short 
arm of the targeting vector. Long arm was composed of XB6.85 and BA773 fragment. The single 
loxP was located in intron III of the relB gene. (B) Schematic diagram of the 18.2 kb targeting 
vector pRelBXS11.2-LLTNL. Open boxes indicate relB genomic sequences; closed boxed 
indicate exons III-VII. XbaI was used for linearization of the targeting vector before 
electroporation. 
 
3.2.1.2  Transfection of mouse embryonic stem cells with the targeting vector 
pRelBXS11.2-LLTNL and Southern blot screening 
After linearization with XbaI, the targeting vector pRelBXS11.2-LLTNL (Figure 3.23 A 
and see Figure 3.22 B) was transfected into E14.1 (from Prof. Wang Z-Q, Lyon, France) 
embryonic stem (ES) cells by eletroporation. Cells were cultured in G418 selection media 
for 9-10 days before being picked (see 2.2.11.2.2). Surviving colonies were expanded for 
freezing and for DNA preparation. The screening strategy is illustrated in schematic 
diagrams in Figure 3.23 A.  
 
Homologous recombination of the targeting vector with wild-type genomic DNA 
introduces an additional 4 kb LTNL cassette into the genome. The SM592 probe [25] was 
located just outside of the targeting vector pRelBXS11.2-LLTNL. This probe 
discriminated a 7.9 kb HindIII DNA fragment, specific for the recombined allele, from a 
14.8 kb DNA fragment, specific for the wild-type relB allele. A total of 550 G418-
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resistant ES clones were picked. Among ~450 ES clones that were screened successfully 
by Southern blotting, no ES clone containing the desired homologous recombination 
(HR) event was found. All G418-resistant ES clones showed the 14.8 kb DNA fragment, 
specific for the wild-type relB allele (Figure 3.23 B). 
 
 
Figure 3.23: Gene targeting of the mouse relB gene using the targeting vector 
pLRelBXS11.2-LLTNL. (A) Schematic diagrams (from top to bottom) of the wild-type relB 
gene locus, the targeting vector, and the homologous recombination allele. Thick lines represent 
relB genomic sequences. Arrows represent the loxP sites and indicate orientation of the loxP sites 
as well. Closed boxes indicate exons III-VII of the mouse relB gene. Cleavage sites for relevant 
restriction endonucleases are indicated. The 3’ external probe (SM592) used for Southern blot 
analysis are indicated by hatched box. The lengths of diagnostic restriction fragments used for 
Southern blotting are also indicated. H: HindIII. (B) Southern blot analysis of genomic DNA 
isolated from G418-resistant ES cell clones. After overnight digestion with HindIII, a 14.8 kb 
DNA fragment recognized by the probe SM592 indicated the wild-type alleles. The 7.9 kb DNA 
fragment indicative for the homologously recombined alleles was not detected. 
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3.2.1.3  Construction of the targeting vector pTVFlox-LRelBXS11.2 and 
screening for HR events 
The targeting frequency of the vector pRelBXS11.2-LLTNL was extremely low as 
indicated by the above work. Only positive selection using G418 was able to be 
performed after transfection due to the presence of the HSVtk gene in the homologously 
recombined alleles. In order to increase the targeting frequency, a second targeting vector 
was generated based on 5.84 kb pTVFlox-0 plasmid (constructed by Dieter Riethmacher 
and Karin Gottschling). This plasmid constitutes the selection marker genes, the neo gene 
flanked by two loxP sites and the HSVtk gene, in a separate pattern (Figure 3.24 A, panel 
1)). Using this plasmid as the backbone of the targeting vector allows a positive-negative 
double selection.   
 
Homologous sequences of the relB gene and the location of the isolated loxP site were 
identical to those of the targeting vector pRelBXS11.2-LLTNL. In brief, the AS3.6 
fragment was the short arm. The long arm was composed of XB6.85 and BA773 
fragment. The single loxP site was located in intron III of the relB gene (Figure 3.24 A, 
panel 2)). The HSVtk gene was located at the end of the short arm AS3.6 (Figure 3.24 A, 
panel 1)) and served as the negative selection marker (using ganciclovir) against ES 
clones, which had randomly integrated the targeting vector.  
 
The cloning procedures for the 17 kb targeting vector pTVFlox-LRelBXS11.2 is 
illustrated in Figure 3.24 A in detail. The homologous sequences (7.6 kb long arm and 
3.6 kb short arm) and the three loxP sites were confirmed by sequencing before 
transfection to ES cells. 
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Figure 3.24: Generation of the targeting vector pTVFlox-LRelBXS11.2. (A) The cloning 
procedures were separated into three steps as listed in panels 1) - 3). AS3.6 fragment was the 
short arm of the targeting vector. The long arm was composed of XB6.85 and BA773 fragment. 
The HSVtk gene was located at the end of the short arm. (B) Schematic diagram of the 17 kb 
targeting vector. The isolated loxP site was located in intron III and the loxP-flanking neo gene 
was located in intron IV of the relB gene. The three loxP sites were in the same orientation. XbaI 
was used for linearization of the targeting vector before electroporation. Open boxes indicate relB 
genomic sequences and closed boxed exons III-VII of the mouse relB gene. 
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3.2.1.4  Transfection of the targeting vector pTVFlox-LRelBXS11.2 into ES 
cells and Southern blot screening 
After linearization with XbaI, the targeting vector pTVFlox-LRelBXS11.2 (Figure 3.25 
A and see Figure 3.24 B) were transfected into E14.1 ES cells by eletroporation. 
Positive-negative selection was performed after the transfection. With this strategy, ES 
clones with a randomly integrated targeting vector can be negatively selected, resulting in 
a 3–5-fold enrichment over G418 selection (positive) alone. Surviving colonies, which 
still manifest a good morphology, were picked carefully under microscope and cultured 
in 96-well plates before freezing at –80ºC.  
 
A total of 450 double-resistant E14.1 ES cell clones were picked and screened 
successfully by Southern blotting. The screening strategy using the 3’ external probe 
(SM592) is described in diagrams in Figure 3.25 A. Homologous recombination of the 
targeting vector pTVFlox-LRelBXS11.2 with wild-type genomic DNA introduced an 
additional 1.2 kb neo cassette into the genome. The SM592 probe distinguished a 6.14 kb 
BamHI DNA fragment, specific for the recombined allele, from a 4.86 kb DNA fragment 
[25], specific for the wild-type relB allele (Figure 3.25 B).  
 
Two ES cell clones were found containing the desired homologous recombination event, 
resulting in a targeting frequency of 1 in 225 double-resistant ES cell clones.  
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Figure 3.25: Gene targeting of the mouse relB gene using the targeting vector pTVFlox-
LRelBXS11.2. (A) Schematic diagrams (from top to bottom) of the wild-type relB gene locus, 
the targeting vector, and the homologous recombination allele. Lines represent relB genomic 
sequences. Arrows represent the loxP sites and indicate orientation of the loxP sites as well. 
Closed boxes indicate exons III-VII of the mouse relB gene. Cleavage sites for relevant 
restriction endonucleases are indicated. The 3’ external probe (SM592) used for Southern blot 
analysis are indicated by hatched box. The lengths of diagnostic restriction fragments used for 
Southern blotting are also indicated. (B) Southern blot analysis of genomic DNA isolated from 
double-resistant ES cell clones. After overnight digestion with BamHI, a 4.86 kb and a 6.14 kb 
DNA fragments, which could be recognized by the 3’ probe (SM592), were generated from wild-
type and homologously recombined alleles, respectively. The homologously recombined ES cell 
clone, termed as #31, is shown. 
 
3.2.1.5  Cre-mediated recombination in the HR ES cells  
In order to obtain ES cell clones containing the floxed alleles, a subsequent transient Cre 
transfection into the homologously recombined ES cell clones (see Figure 1.12 and 
Figure 3.21) is necessary to be performed.  
 
 94
                                                                                                                                    Results 
Twenty-five µg supercoiled pGK-Cre plasmid was transfected into the homologously 
recombined ES cell clone (#31) by electroporation. Cells were cultivated for three to four 
days before being picked. Upon Cre transfection, three individual recombination events 
among three loxP sites took place (see Figure 1.12). The aim of screening was to get the 
ES cell clones containing the floxed alleles (relBflox/+ cells), in which recombination 
events occurred between the loxP sites flanking the neo cassette.  
 
The Southern blot screening strategy is described in Figure 3.26 A. The recombination 
events, which happened between the loxP sites flanking the neo cassette, resulted in the 
exclusion of the 1.2 kb neo cassette from the HR allele. This event left one loxP site in 
intron IV of the relB gene which generated, together with the isolated loxP site in the 
intron III, the floxed version of the relB gene (type I, see Figure 1.12). The SM592 probe 
recognized a 4.86 kb BamHI DNA fragment, indicative of the floxed allele (Figure 3.26 
B). ES clones containing the floxed allele were further confirmed in Southern blots of 
HpaI/HindIII-digested DNA hybridized with SM592. A 9.7 kb band indicated the floxed 
allele (data not shown). The wild-type alleles also gave rise to a 4.86 kb BamHI DNA 
fragment as shown in Figure 3.26 B. The Cre transient transfection was performed in HR 
cells. It was unlikely that the 4.86 kb BamHI DNA fragment came from wild-type ES 
cells. Nevertheless, to make sure that this fragment was contributed by the floxed allele 
(relBflox/+ cells) rather than by the contamination of wild-type cells, a PCR-based 
screening strategy was generated as well. The PCR reaction amplified sequences 
spanning the isolated loxP site in intron III of the relB gene (see 2.1.4.2), generating one 
200 bp band from wild-type cells, but an additional 243 bp band from HR and relBflox/+ 
cells (Figure 3.26 B).  
 
Cells containing the deleted alleles, in which the recombination events happened between 
the outer loxP sites leading to the mutation of the relB gene, produced a 9.7 kb band by 
BamHI/HindIII digestion in Southern blotting (Figure 3.26 A). 
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Figure 3.26: Transient Cre transfection into HR ES cell clones. (A) Schematic diagrams (from 
top to bottom) of the wild-type relB gene locus, the homologous recombination allele, the floxed 
allele, and the deleted allele. PCR amplification is indicated with arrows in diagrams of the wild-
type and floxed allele. (B) The Southern blotting and the PCR results, the first lanes indicate the 
wild-type clone, the middle lane the homologously recombined clone, and the right lanes the 
floxed clone. 
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3.2.1.6  Blastocyst injections and breeding of chimeras 
E14.1 ES cell clones, which were identified to carry the relBflox/+ allele, were cultured and 
injected into blastocysts subsequently (see Figure 3.12) by Ms. Yvonne Peterson 
(ITG/FZK, Karlsruhe). The blastocysts (C57BL/6J; black coat color) and E14.1 ES cell 
line (129/Ola; agouti coat color) were from different mouse lines. Chimeric animals with 
a different coat color were expected to be generated upon the integration of embryonic 
stem cells. The degree of chimerism indicates how many ES cells contribute to the 
transgenic animals and can be estimated by the coat color. More than 20 chimeras with 
different degree of chimerism were generated; unfortunately, none of them transmitted to 
germline. 
 
3.2.2  Generation of cre-transgenic mice that specifically express 
Cre in LTβR-positive cells 
To establish mouse models in which the activation of RelB or RelA complexes by LTβR 
can be selectively blocked,  transgenic mouse lines that express the Cre recombinase 
under the control of LTβR regulatory elements need to be generated (see Figure 3.20). 
 
Cre transgenic mice can be generated either by pronucleus injection of randomly 
integrating transgene constructs or by targeted introduction of the cre recombinase gene. 
The former method is more convenient. However, the promoter region for transgenic 
expression must be available. Moreover, in order to identify a decent mouse strain, it is 
necessary to generate different founder lines. The number of these founder lines is 
unpredictable since the level and the pattern of transgene expression vary greatly, mainly 
depending on copy number and integration site. The gene targeting-based cre “knock-in” 
approach, which drives Cre expression by the endogenous gene regulation, is much more 
reliable but, certainly, more complicated and troublesome. In addition, the disadvantage 
of the gene-targeting cre knock-in is that they create a mutation in the endogenous gene, 
which may affect further applications. 
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3.2.2.1  Generation of ltbr-cre transgenic mice  
The promoter of the mouse ltbr gene is defined. About one kb 5’ flanking region of the 
mouse ltbr gene has been functionally analyzed. The -938 bp to -1 bp ltbr promoter 
construct shows a 35-fold higher luciferase activity in NIH 3T3 cells and a 15-fold higher 
activity in RAW 264.7 cells compared to control plasmids, confirming the functional 
promoter activity in both cell lines. The transcriptional start site of the mouse ltbr gene is 
located at -60 bp [128].  
 
A 1.25 kb genomic DNA fragment, spanning from –938 bp to 5’-end of exon II (+318 
bp) of the mouse ltbr gene, was amplified by PCR and subcloned into plasmid 
pBluescript SK(+). The first ATG codon of the ltbr gene was mutated by the site-directed 
mutagenesis method (Stratagene) in order to ensure sufficient transcription from the first 
ATG of cre. The 1.25 kb PCR products and the point mutation were confirmed by 
sequencing. Plasmid pGKcreNLSbpA was used to isolate the cre-coding sequences 
including the nuclear localization (NLS) and the polyadenylation signal (bpA). The 1.2 
kb cre cDNA fragment was then cloned into 3’ of the ltbr promoter region (Figure 3.27 
B). The 2.45 kb NotI fragment was isolated from the transgene construct with NotI 
digestion and eletroeluted from agarose gel for pronucleus injection.  
 
Among 21 mice borne, 4 mice were found containing the ltbr-cre transgene by PCR 
genotyping (Figure 3.27 C). These four founder lines were further confirmed by 
Southern blot analysis of NotI-digested tail DNA using a 1.2 kb probe, hybridizing with 
the cre-coding sequences (Figure 3.27 D). 
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Figure 3.27: Generation of ltbr-cre transgenic mouse. (A) The mouse ltbr gene contains 10 
exons spanning 6.9 kb and maps to mouse chromosome 6. Open boxes indicate ltbr genomic 
sequences. Closed boxes indicate exons I-X of the mouse ltbr gene. (B) The ltbr-cre transgene 
construct. The cre-coding sequences were coupled to the ltbr promoter region extending to 5’-end 
of exon II. The ltbr promoter drove cre transcription in LTβR-expressing cells in theory. 
Digestion sites for relevant restriction enzymes are indicated. (C) PCR analysis of tail DNA. In 
ltbr-cre transgenic mice, a 340 bp band was detected along with a 450 bp wild-type band. The 
details for PCR genotyping are described in 2.1.4.3. (D) Southern blot analysis. Tail DNA from 
transgenic (line 4, 11, 12, and 13) and wild-type mice was digested overnight with NotI and 
hybridized with a 1.2 kb cre probe.  
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3.2.2.2  Characterization of ltbr-cre transgenic mouse lines 
For identification of a cre-transgenic strain suitable for further experiments, it is 
necessary to produce a series of transgenic mice with the same construct and to compare 
the efficiency and specificity of the Cre-mediated recombination among these founders. 
To address the efficiency of the ltbr regulatory elements, which are supposed to drive the 
expression of Cre recombinase specifically in LTβR-expressing cells, the mRNA levels 
of cre and endogenous ltbr in various tissues from different transgenic founder lines were 
analyzed.  
 
ltbr mRNA is detectable in developing sinus, sub maxillary gland, thymus, lung, 
stomach, gut, and muscle in an E16.5 mouse embryo. In the developing thymus, ltbr 
mRNA are detected in both cortical and medullar thymic regions. ltbr mRNA is 
expressed ubiquitously in adult mice and a high level of ltbr expression is found in liver, 
lung, and kidney by Northern blotting [129-131]. 
 
Similarly, a universal tissue distribution of ltbr mRNA was detected in wild-type and 
ltbr-cre transgenic mice by real-time PCR (data not shown and Figure 3.28). The highest 
ltbr expression was found in livers. The ltbr expression in lung and kidney is also higher 
than that in other tissues.  
 
The cre expression pattern in the offspring from each transgenic line was analyzed by 
real-time PCR. cre mRNA was detected in several tissues as well, including thymus 
(TH), spleen (SP), mesenteric lymph node (LN), liver (LI), lung (LU), kidney (KI), skin 
(SK), stomach (ST), and intestine (IN, without PPs). In founder line 13, 12, and 11, the 
tissue expression pattern of cre mRNA was consistent with that of endogenous ltbr 
mRNA (Figure 3.28).  
 
These observations suggest that the ltbr regulatory elements in certain ltbr-cre transgenic 
lines were functionally active and able to drive appropriate Cre expression specifically in 
LTβR-expressing cells. In addition, a similar expression level of cre mRNA, especially in 
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lymphoid organs such as thymus, spleen, and lymph node was observed in ltbr-cre 
transgenic line 12 and 13. 
 
 
Figure 3.28: Tissue distribution of cre and endogenous ltbr mRNA in ltbr-cre transgenic 
lines by real-time RT-PCR. Numbers in tables below the bar charts indicate the relative mRNA 
expression levels in individual tissues. Data represent at least two offspring from each transgenic 
line. Line 13 and 12 were chosen to breed with reporter (R26R) mice.  
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The accurate assessment of a tissue-specific cre transgenic mouse is highly dependent on 
the availability of a reliable reporter mouse line. The R26R mouse line, in which the 
ROSA26 locus has been targeted with the floxed neo cassette and the lacZ gene, is 
widely used for monitoring the Cre expression [132]. Upon breeding the R26R mouse 
with a Cre-expressing transgenic mouse, Cre-mediated deletion of the floxed neo cassette 
activates the transcription of the lacZ gene. The lacZ expression can be detected by 
staining tissues for β-galactosidase (β-Gal) activity. A positive lacZ signal is only visible 
in cells expressing functional Cre protein. 
 
Two founder lines (13 and 12), in which the cre mRNA expression largely reflected that 
of the endogenous ltbr expression, were selected to breed with a reporter mouse line 
(R26R) for further characterization. Breeding ltbr-cretg mice with R26R mice result in a 
restricted lacZ expression pattern, which can then be detected histo-chemically upon Xgal 
staining. Thus, the expression pattern of lacZ indicates the ltbr promoter activity and 
further reflects the ltbr expression pattern. A wide range of tissues from individual ltbr-
cretg/R26R transgenic line was collected for this analysis. 
 
3.2.2.3  Generation of ltbr-cre knock-in mice  
As an alternative method to the conventional transgenic approach by pronucleus 
injection, Cre expression can be brought under the control of an endogenous promoter by 
homologous recombination in ES cells. Using this strategy, Cre expression becomes 
optimally regulated since all control elements of the targeted gene are present at their 
natural chromosomal position. Therefore, inappropriate transgene expression, which is 
often encountered with the conventional strategy especially when the promoter is not well 
characterized, can be avoided. 
 
The ltbr-cre knock-in targeting vector pTVFlox-LTβR-Cre was constructed based on the 
plasmid pTVFlox-0. A 6.5 kb long arm was amplified from plasmid pLTβR by PCR 
using eLONGase enzyme mix and subsequently inserted into 3’ of the floxed neo cassette 
in pTVFlox-0 plasmid. A 1.25 kb fragment (short arm), spanning from –938 bp to the 5’-
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end of exon II (+318 bp) of the mouse ltbr gene, was amplified from plasmid pLTβR as 
well. The first ATG codon was mutated as described before. The 1.25 kb PCR products 
were confirmed by sequencing. The 1.2 kb cre coding region, including the NLS and a 
bpA, was isolated from plasmid pGKcreNLSbpA (see Figure 3.27). Then, the 2.6 kb NotI 
fragment was inserted into 5’ end of the floxed neo cassette. The tk gene was located at 
the end of long arm of the targeting vector (Figure 3.29). 
 
 
Figure 3.29: Schematic diagram of the ltbr-cre knock-in targeting vector pTVFlox-LTβR-
Cre. The first ATG of the mouse ltbr gene was mutated so that the translation initiation codon of 
cre can be used. The neo gene flanked by the loxP sites was inserted downstream of cre coding 
sequences. The tk gene was located at the end of the 6.5 kb long arm. Open boxes represent ltbr 
genomic sequences. Arrows represent the loxP sites and indicate the orientation of the loxP sites 
as well. Closed boxes represent exons I-X of the mouse ltbr gene. Cleavage sites for relevant 
restriction endonucleases are indicated. PacI can be used for linearization of the targeting vector 
before electroporation. The floxed neo gene will be deleted from the targeted locus upon the 
transient expression of Cre recombinase (see Figure 3.30 A).  
 
The Southern blot strategies for screening the homologously recombined allele and the 
deleted allele upon transient Cre transfection in HR ES cells are described in detail in 
Figure 3.30 A. Procedures for cloning the 550 bp 5’ external probe (RX550) are 
illustrated in Figure 3.30 B.  
 
Due to the absence of germline transmission with pTVFlox-LRelBXS11.2 construct, the 
transfection of the ltbr-cre knock-in targeting vector pTVFlox-LTβR-Cre was postponed 
until promising ES cells are available.  
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Figure 3.30: (A) Southern blot screening strategy for the targeting vector pTVFlox-LTβR-
Cre. Schematic diagrams (from top to bottom) of the wild-type ltbr gene locus, the targeting 
vector, HR allele, and the deleted allele upon Cre transfection. The 5’ external probe, Neo probe, 
and Cre probe for Southern blot hybridization are indicated by hatched boxes. EcoRV (RV) and 
EcoRI (RI) were used for digestion in Southern blot analysis. (B) Cloning of the 5’ external 
probe (RX550). 
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4  Discussion 
4.1  Role of Rel/NF-κB transcription factors in B 
lymphopoiesis  
Rel/NF-κB transcription factors play a central role in the immune system. Members of 
this family are involved in many aspects of B-cell maturation and function. A patterned 
expression of Rel/NF-κB proteins in the process of B-cell differentiation was found from 
the analysis in individual B-cell lines and murine splenic B cells: mainly p50 and RelA 
(p65) in pre-B cells, a predominance of c-Rel and p50 in mature B cells, and expression 
of p52 and RelB in terminally differentiated cells [103]. This ordered pattern suggests the 
requirements for distinct Rel/NF-κB family members in different stage of B-cell 
maturation.  
 
The role of NF-κB signaling pathway in B-cell development and function has been 
studied for nearly two decades. Mice lacking individual Rel/NF-κB family members 
manifest phenotypes restrictive to mature B-cell activation. Almost no clear 
abnormalities in the process of B-cell differentiation have been observed (see Table 1-3) 
likely due to functional redundancy among these transcription factors. Nevertheless, 
subtle perturbations in the generation of particular B-cell subsets are found. For example, 
nfkb1-/- mice have no MZ B cells and peritoneal B1 cells [98].  
 
nfkb2-/- mice have a dramatic reduction in the absolute number of B cells in periphery 
such as spleen and lymph nodes. The number of nfkb2-/- B cells in bone marrow reduces 
~50% between 8 and 12-week of age. Proliferation of nfkb2-/- B cells is moderately 
reduced in response to LPS, anti-IgD-dextran, and CD40. nfkb2-/- B cells display normal 
cell maturation to immunoglobulin secretion and class switching in vitro [22, 23]. The 
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MZ formation in nfkb2-/- mice is impaired. MZ B cells were partially reduced (data not 
shown). 
 
relB, encoding one of Rel/NF-κB family members, has originally been identified as an 
immediate early gene. RelB is expressed in later stages of B-cell maturation and can bind 
to regulatory sites within the Ig heavy chain locus. relB-/- mice display a complex 
phenotype, including multifocal defects in immune responses, impaired natural killer T 
(NKT) cells [133] as well as myeloid dendritic cells (DC) differentiation, and defective 
secondary lymphoid organogenesis. RelB, like c-Rel, p50, and p52, plays a role in B-cell 
proliferation. B cells lacking RelB show a reduction in DNA synthesis in response to 
LPS, CD40, and membrane Ig-dependent activation. relB-/- B cells are normal in their 
ability to undergo maturation to IgM secretion and switch to the expression of IgG3, 
IgG1, IgG2b, IgG2a, IgE, and/or IgA [134]. In addition, RelB, similar to p50, is required 
for MZ B-cell development in a cell-autonomous manner [107].  
 
Taken together, NF-κB2 (p100 and p52) and RelB is indeed involved in the activation of 
mature B cells and the development of certain B-cell subsets. However, the involvement 
of NF-κB2 and RelB in mainstream B-cell development, especially at early stage has not 
been well studied.  
 
4.1.1  The involvement of alternative NF-κB activation pathway in 
mainstream B-cell development  
The alternative NF-κB pathway activates p52/RelB heterodimers. Upon given signals 
such as BAFF in mature B cells [110], the C-terminal domain of the precursor p100 is 
proteolytically processed and degraded in a NIK-IKKα dependent manner (Figure 1.2). 
Consequently, p52/RelB heterodimers translocate to nucleus and bind to κB motifs in 
their target genes. Therefore, NF-κB2/p100 functions as a specific and potent inhibitor of 
RelB. Mice lacking p100 (still generating p52, see Figure 1.3), thus, provide a good 
system for investigating intensively the function of alternative NF-κB pathway (NF-
κB2/p100 and RelB) with a special focus on mainstream B-cell development. 
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Strikingly, B-cell development was found being arrested almost completely at an early 
pro-B stage (Fr. A/B) in mice deficient of p100 (see Figure 3.2). The reduced frequency 
of B220+CD19+ cells in p100-/- mice was unlikely owing to increased apoptosis since the 
percentage of Annexin-V positive cells among this population was similar to that in wild-
type mice (data not shown). The impaired B-cell differentiation in bone marrow resulted 
in a reduction of peripheral B lymphocytes. Moreover, p100 was required in a cell-
intrinsic manner within B-lineage precursors for appropriate B-cell development as 
indicated by competitive bone marrow transplantation experiments (see Figure 3.3 and 
3.4).  
 
RelB heterodimers bound constitutively to κB motifs in various lymphoid tissues when 
p100, the inhibitor of RelB was deleted (see Figure 3.5). Interestingly, the elevated RelB 
DNA-binding activity in p100-/- mice was recovered to wild-type levels when one allele 
of the relB gene was inactivated in these mice (p100-/-relB-/- mice), correlated with the 
rescued B-cell development (see Figure 3.6 and 3.8). The study here, as first time, 
pinpoints that the strength of RelB DNA-binding activity functions crucially in B 
lymphopoiesis. High levels of RelB activity (p100-/-) blocks B-cell development at an 
early stage; normal (medium) levels of RelB activity (p100-/-relB-/+) favor this process; 
absence of RelB activity (p100-/-relB-/- and relB-/-) affects B-cell activation and survival 
rather than mainstream B-cell development. Thus, the tightly regulated p100 processing 
in alternative NF-κB activation pathway in B-lineage precursors is an important event in 
B-cell development.  
 
The involvement of the alternative NF-κB activation pathway in B-cell development is 
not well defined. This pathway does take place in peripheral B cells upon triggering of 
certain receptors such as BAFF-R and CD40. The p100 processing triggered by BAFF-R 
is initiated at the T1 stage, with the highest levels of p52 in T2 and mature B cells ( see 
Figure 1.9) [110]. BAFF-deficient mice have a nearly complete block in B-cell 
differentiation at the T1 to T2 transitional stage in spleen, with subsequent loss of T2, 
FO, and MZ B cells [135, 136]. The T2 and MZ B-cell compartments are particularly 
enlarged in BAFFtg mice, which are prone to autoimmune diseases [137, 138]. In nfκb1-/-
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nfκb2-/- double knockout mice, B-cell development is also blocked at the T1 stage in 
spleen due to the failure of receiving BAFF signaling (Figure 4.1 and see Figure 1.9) 
[31].  
 
The CD40-TRAF2 signaling evidences the involvement of the alternative NF-κB 
activation pathway in the generation of mature B cells as well [139]. TRAFs (TNFR-
associated factors) belong to a family of adaptor proteins that transmits many signals 
delivered by TNFR. TRAF2 is essential for the CD40-mediated activation of the classical 
NF-κB pathway in primary B cells [140-143]. Recently, it is shown that TRAF2 actually 
functions as a multifunctional regulator of NF-κB activation. It mediates activation of the 
classical NF-κB pathway, but also acts as a negative regulator of the alternative NF-κB 
pathway. The constitutive p100 processing and increased p52/RelB DNA-binding activity 
are displayed in TRAF2-deficient B cells. B cells lacking TRAF2 possess a selective 
survival advantage, resulting in an accumulation preferentially in lymph nodes and 
marginal zone [142, 144]. This phenotype mirrors the observations in mice that 
overexpress BAFF.  
 
Thus, constitutively activated alternative NF-κB pathway upon given signals, which 
results in increased p52/RelB DNA-binding activity, functions importantly in the 
generation of peripheral mature B cells. From the observations of this study, the 
importance of the alternative NF-κB activation pathway in the generation of bone marrow 
B-cell precursors is demonstrated in vivo (Figure 4.1). 
 
On the other hand, the involvement of the classical NF-κB activation pathway in B-cell 
development has been suggested by distinct phenotypes in mice lacking different 
combination of NF-κB proteins. This pathway mainly activates p50/RelA heterodimers 
via IKK-mediated IκBα phosphorylation and subsequent ubiquitination and degradation. 
In chimeras engrafted with RelA-deficient fetal liver cells, a massive decrease of fetal 
liver-derived B220+ B-cell precursors in bone marrow and a moderate decrease of 
peripheral B lymphocytes are observed [145]. The almost absence of B220+ B-cell 
precursors in chimeras engrafted with nfkb1-/-relA-/- fetal liver indicates that p50 and 
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RelA, not in a cell-autonomous manner, regulates the emergence of B220+ B-lineage 
precursors (Fr. A1, Figure 1.9) [105]. RelA/c-Rel heterodimers, which is also activated 
in NF-κB classical pathway, do not affect the generation of B-lineage progenitors; rather, 
RelA and c-Rel serve redundant functions in regulating survival and differentiation of B 
lymphocytes at the transition from T2 to mature B cells in spleen [33]. 
 
Collectively, our knowledge about the function of alternative NF-κB activation signaling 
pathway in B cells is primarily restrict to the peripheral mature B cells. The observations 
in this study broaden our understanding of the function of alternative NF-κB pathway 
(NF-κB/p100 and RelB) in the context of early B-lymphocyte development. Moreover, 
individual NF-κB complexes do serve distinct roles at different checkpoints during B-cell 
maturation. While p50/RelA complexes (classical pathway) are known predominantly 
involving in the generation of B220+ B-lineage progenitors (Fr. A1), p52/RelB complexes 
(alternative pathway), for the first time, are found playing an important role in the 
generation of B220+ CD19+ B cells (Fr. B) in bone marrow (Figure 4.1). 
 
 
Figure 4.1: Model for the roles of Rel/NF-κB members in B-cell development. Individual 
Rel/NF-κB complexes do serve distinct roles at different checkpoints during B-cell maturation. 
The stages of B-cell development, in which the alternative Rel/NF-κB activation pathway (p100 
and RelB) functions, are indicated by dashed lines in blue. 
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4.1.2  Enhanced RelB DNA-binding activity represses the 
expression of certain B-lineage commitment genes  
The development and selection of B lymphocytes are complex processes that are initiated 
in embryo and proceed throughout life to provide organism an essential part of the 
immune system. A large number of different transcription factors have been linked to 
distinct stages in the life of B lymphocytes, such as differentiation in bone marrow, 
migration to peripheral organs, and antigen-induced activation. 
 
Three transcription factors have been identified playing crucial roles at the onset of B-cell 
development by gene targeting: EBF, E2A, and Pax5. E2A and EBF act upstream of 
Pax5 in the genetic hierarchy of B-cell development and are equally expressed in Pax5-/- 
and wild-type pro-B cells. Mutation of Pax5 is considered to dissociate the initial 
activation of B-lineage-specific gene expression by E2A and EBF from the Pax5-
dependent control of B-lineage commitment [56]. Inactivation of any of these three genes 
leads to a block in B lymphopoiesis before complete rearrangement of the 
immunoglobulin heavy chain gene (see Figure 3.10). 
 
The findings in this study indicate that B-cell development is arrested at early pro-B stage 
(Fr. B) in the absence of p100 owing to the increased RelB activity. Interestingly, a 
downregulated expression of EBF and Pax5 and an intact expression of E2A mRNA in 
p100-/- pro-B cells were found (see Figure 3.10). This disturbed expression pattern of B-
lineage transcription factors was restored when one allele of the relB gene in p100-/- mice 
was deleted (p100-/-relB-/+), correlated with the rescued B-cell development in these 
mice. Taken together, p100 does regulate the transcription of Pax5 and EBF, but not E2A. 
The impaired B-cell development in p100-/- mice is likely due to the reduced expression 
of B-lineage transcription factors EBF and Pax5, which is caused by the constitutively 
increased RelB activity. Thus, RelB behaves as a physiological repressor of Pax5 and 
EBF (Figure 4.2).  
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Low expression of EBF could functionally cooperate with the intact E2A, enabling B-
lineage precursors differentiate through pre-pro-B stage. However, most of these pre-pro-
B precursors fail to express CD19 and progress to the late stage since Pax5 activity is 
extremely low. CD19 expression is known to be an indicator of Pax5 activity [126, 146]. 
This may explain why the B-cell developmental defect observed in p100-/- mice is similar 
to that in Pax5-/- mice but not to that in EBF-/- or E2A-/- mice. The molecular mechanism 
by which RelB represses the expression of Pax5 and EBF is currently unknown and 
requires future investigation. A κB binding site was found in the EBF promoter region 
but not yet in the Pax5 promoter (date not show). 
 
Interestingly, an arrested B lymphopoiesis, which is exactly same as p100-/- mice, has 
been observed in il-7-/- and  il-7rα-/- mice [147, 148]. IL-7R is initially expressed on CLP 
but not on CMP or multipotent stem cells [149]. Signaling through IL-7R is necessary for 
both B- and T-lineage development [150]. Strikingly, it is shown that the ectopic 
expression of IL-7R in hematopoietic progenitors causes a severe block in B-cell 
differentiation at the early pro-B stage [151]. These developmentally arrested IL-
7R+B220+CD19- cells fail to express EBF and Pax5, suggesting that the transient 
downregulation of IL-7R expression in the process of B-cell differentiation is necessary 
for the induction of EBF and Pax5 expression and for the B-cell commitment. Very 
recent report show that il-7-/- CLPs express lower EBF and Pax5 than wild-type CLPs. 
Overexpression of EBF in il-7-/- cells is sufficient to restore the B-cell potential, 
indicating that IL-7 directs commitment of CLPs by regulating EBF expression [152].  
 
The similarities between p100-/- and il-7-/- as well as il-7rα-/- mice in terms of B-cell 
development, together with the reduced expression of EBF and Pax5 in p100-/- mice 
suggests a correlation between p100 and IL-7 signaling. IL-7R was expressed in 
B220+CD43+CD19- p100-/- pro-B cells. Moreover, transcription of both IL-7 and IL-7Rα 
was intact (data not shown). Whether that p100 processing, leading to the constitutive 
p52/RelB nuclear translocation, is a downstream event of IL-7R signaling in B-cell 
precursors is currently unknown. Preliminary data suggested that IL-7 could induce p100 
production and p100 processing in primary wild-type pro-B cells (data not shown). 
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Nevertheless, the above observations were not found in established B-cell lines, for 
example, BaF3 (pro-B-cell line) and 70Z/3 as well as WEHI 231 (pre-B-cell lines). 
Further studies are required to address that whether IL-7R signaling regulates p100 
processing to p52, which further affects the expression of B-lineage transcription factors 
in B-cell precursors. 
 
4.1.3  The lymphoid-myeloid potential of p100-/- pro-B cells 
Classic model of hematopoietic differentiation state that stem cells become gradually 
restricted in their differentiation potential by a succession of symmetric and asymmetric 
divisions. Each intermediate progenitor has a distinct gene expression program, which is 
maintained by specific transcription factors. Once a cell commits to a particular lineage, 
it can no longer change its fate.  
 
There are numerous reports demonstrate that the committed hematopoietic cells can be 
induced converting into other lineages [153]. A surprising degree of plasticity is 
discovered in Pax5-/- pro-B cells: on one hand, these cells exhibit characteristics of early 
pro-B cells (B220 , c-Kit+ low, CD43+, and CD19-). On the other hand, they have 
characteristics of pluripotent stem cells. They are able to undergo self-renewal on stromal 
cells in IL-7 cultures, home to bone marrow after transplantation, and differentiate into 
other cell types in vitro and in vivo (see Figure 1.6) [126, 154]. More strikingly, recent 
work shows that enforced expression of C/EBPα or C/EBPβ in differentiated B cells 
results in their rapid and efficient reprogramming into myeloid cells. C/EBPs induce 
these processes by inhibiting Pax5, leading to the downregulation of its target CD19, and 
synergizing with endogenous PU.1, leading to the upregulation of Mac-1 and other 
myeloid markers [91]. The myeloid specific gene M-CSFR is regulated by three 
transcription factors including C/EBP, PU.1, and AML1. They interact with critical 
regions of the M-CSFR promoter. AML1 is involved in several common leukemia-
related chromosome translocations. A physical interaction between C/EBP and AML1 is 
revealed by in vitro binding analysis [155] .  
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The similarity between p100-/- and Pax5-/- mice in terms of early B-cell development 
raises the possibility that p100-/- pro-B cells may also have the lymphoid-myeloid 
potential similar to Pax5-/- pro-B cells (see Figure 1.6). This assumption was confirmed 
by the observation that p100-/- pro-B cells could differentiate into Mac-1+ cells even in 
the IL-7 cultures which supports B-lymphocyte proliferation and differentiation. The 
significantly increased expression of C/EBPα in p100-/- pro-B cells was a possible reason 
for the transition potential of p100-/- pro-B cells.  
 
In summary, it is likely that elevated RelB activity in B-lineage progenitors due to the 
lack of p100 inhibitor, on one hand, suppresses the expression of B-lineage transcription 
factors EBF and Pax5, switching off the B-lineage differentiation program, on the other 
hand, induces the expression of C/EBPα, switching on the reprogramming machinery of 
p100-/- pro-B cells. Alternatively, the reduced Pax5 expression could be a sequential 
event in the process of p100-/- pro-B cells transdifferentiation to myeloid cells, which is 
driven by the increased C/EBPα activity (Figure 4.2). To unravel the molecular 
mechanism by which RelB represses the expression of Pax5 as well as EBF and induces 
the expression of C/EBPα in B-cell progenitors will be very interesting and constructive. 
The severe myeloid hyperplasia observed in p100-/- mice (see Figure 3.12) is then 
assumed rising from the converting of p100-/- pro-B cells to myeloid cells. The potential 
of p100-/- pro-B cells in differentiation to other cell types, for example, osteroclasts, T-
lymphocytes will also be studied in the near future. 
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Figure 4.2: Model for B-lineage development and B-lineage versus myeloid-lineage 
conversion. Vertical bars in red indicate the B-cell development blocks at different stages. 
Straight arrows and T-shaped bars indicate activation and inhibition, respectively. Dashed lines 
indicate uncertainty. 
 
4.1.4  Other B-cell subsets affected in p100-/- mice  
MZ B cells function as a first line of defense, along with B1 B cells, against blood-borne 
pathogens. This B-cell subset helps to bridge the temporal gap between an innate immune 
response and a primary, T-cell dependent, adaptive antibody response. The generation 
and/or retention of MZ B cells is still largely unknown although recent studies using 
mutant mouse models underscore a direct or indirect involvement of certain signaling 
pathways (see Table 1-2). There are two major driving forces for normal MZ B-cell 
development [99, 156]. One determinant is the specificity of B-cell receptor (BCR), 
which allows a developing B cell to choose between FO and MZ B-cell fate. Another 
important factor is Notch signaling [157, 158]. B cells differentiate into MZ B-cell 
lineage when they receive additional signals from Notch2.  
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Weak BCR signaling favors the generation of MZ B cells, whereas strong signal favors 
that of FO B cells. NF-κB1/p50 is required in a cell-autonomous manner for the 
generation of MZ B cells. The loss of either RelA or c-Rel leads to a less severe reduction 
in MZ B-cell numbers. RelB, in terms of p52/RelB heterodimers in stromal cells 
downstream of LTβR, contributes to MZ microarchitecture formation. RelB is required 
for MZ B-cell development in a cell-autonomous manner. It is possible, therefore, that 
p50/RelB heterodimers are required downstream of weak signals delivered by BCR for 
the normal MZ B-cell development and survival [99].  
 
An accumulation of MZ B-cell subset in a cell-intrinsic manner in p100-/- spleen was 
found in this study; in spite of a reduction in the number of transitional B cells (see 
Figure 3.17). The origin of MZ B cells is not well understood. It is generally believed 
that T2 B-cell population includes presumed MZ B-cell precursors, which further 
differentiate into MZ B cells [48, 94, 159]. It is unlikely, however, that the increment of 
splenic MZ B cells in p100-/- mice is differentiated from T2 B cells due to the reduction 
of T1 and T2 B-cell populations in these animals. The increased RelB function in the 
form of p50/RelB heterodimers in p100-/- B cells may play a role downstream of weak 
BCR signaling in the generation of MZ B cells. Unlike mainstream B-cell development, 
the impaired MZ B-cell development was only partially rescued when one allele of the 
relB gene was deleted in p100-/- mice. The p50 activity in theses mice may support the 
generation of MZ B cells. 
 
Mammals have four Notch receptors encoded by four different genes (Notch1–4) [160, 
161]. In early embryonic development, Notch is crucial for generation of hematopoietic 
stem cells. During hematopoiesis and immune development, Notch is critical for T/B 
lineage decision and for generation of splenic MZ B cells. The function of Notch receptor 
in the T/B-cell lineage decision is Notch1 specific [162, 163]. Notch2 is the predominant 
Notch receptor in B cells, with widespread expression throughout B-cell development 
and in peripheral B-cell subsets [158, 164]. Notch2 signaling plays a positive and 
essential role in the development of MZ B cells and B1 B cells [164-166]. B cell-specific 
deletion of Notch2 leads to a dramatic loss of MZ B cells. In addition, B cell-specific 
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deletion of MINT-1, an inhibitor of Notch signaling [167], leads to an increase in MZ B 
cells [168]. Thus, Notch2 activity determines the fate of MZ B cells. The loss-and-gain 
RelB activity on the generation of MZ B cells mirrors that of Nothch2. No MZ B cells 
developed in p100-/-relB-/- and relB-/- mice (see Figure 3.19). An increased number of 
MZ B cells were observed in mice lacking the specific inhibitor of RelB, p100 (see 
Figure 3.17). However, the unaffected expression pattern of Notch2 and MINT in p100-/- 
splenic B cells suggests that the increase of MZ B cells in p100-/- mice was independent 
of Notch2 signaling (data not show). 
 
It has been hypothesized that bottlenecks in B-cell development (defective development 
of mainstream B cells) leads to increased MZ B cells. These observations have been 
found in il-7-/-, il-7rα-/-, and immunoglobulin λ-chain 5 (λ5)-/- mice [169, 170], in which 
the development of mainstream B cells is blocked, along with the enlarged MZ B-cell 
compartment. In p100-/- mice, the similar phenotype, in terms of generating mainstream B 
cells and MZ B cells, is in line with the ‘bottleneck hypothesis”.   
 
Taken together, the findings in this study give a better insight into the specific role of 
alternative NF-κB activation pathway (NF-κB2/p100 and RelB) with respect to B-
lymphocyte development. Each NF-κB activation pathway functions distinctively and 
critically in the development and the activation of B cells. p50/RelA (classical pathway), 
known from previous studies, is mainly involved in the generation of B220+ B-lineage 
progenitors (Fr. A1). From this study, it is demonstrated that p52/RelB activity 
(alternative pathway) regulates the emergence of B220+ CD19+ B cells (Fr. B) in bone 
marrow and the generation of MZ B cells in spleen (Figure 4.1). The elevated RelB 
activity in B-lineage progenitors due to the lack of p100 inhibitor suppresses the 
expression of B-lineage transcription factors EBF and Pax5, switching off the B-lineage 
differentiation program. The increased RelB function determines the fate of B 
lymphocytes versus myeloid cells likely attribute to the induction of C/EBPα expression 
(Figure 4.2). In conclusion, the tightly regulated p100 processing in alternative NF-κB 
activation pathway in B-lineage precursors is an important event in B-cell development 
and B-lymphoid/myeloid-lineage decision.  
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4.2  Generation of mouse models to investigate the role of 
Rel/NF-κB signaling pathways in secondary 
lymphoid organogenesis 
The secondary lymphoid organs include spleen, lymph nodes, and organized lymphoid 
tissues associated with mucosal surfaces such as Peyer’s patches. The development of 
secondary lymphoid organs requires the proper function of certain molecules within a 
defined timeframe during ontogeny. The activation of NF-κB pathway through LTβR has 
been demonstrated functioning crucially in this process.  
 
The activation of LTβR in stromal cells by LTα1β2 on hematopoietic cells induces the 
classical as well as the alternative NF-κB signaling pathway [120]. The activation of 
p50/RelA heterodimers in the classical pathway depends on IKKβ–IKKγ subunits-
mediated degradation of IκBα. In contrast, the activation of p52/RelB heterodimers 
through the alternative pathway requires NIK-IKKα dependent p100 processing.  
 
The expression of p52 and RelB is restricted to specific regions of lymphoid organs, 
consistent with the constitutive basal p52/RelB DNA-binding activity in these tissues 
[171]. RelB-deficient mice display an impaired lymphoid organogenesis including lack of 
LNs and PPs as well as disorganized spleen microarchitectures [17, 107], suggesting that 
RelB complex functions importantly in the generation and the maintenance of intact 
structure of these organs. A similar phenotype is observed in nfκb2-/- mice [22, 23] but 
not in nfκb1-/- mice [21]. The role of RelA in secondary lymphoid organogenesis is less 
understood due to the embryonic lethality of relA-/- mice. In relA-/-tnfr1-/- mice, the early 
lethality is rescued. These mice manifest a defective lymphoid organ development. 
However, TNFR1 itself contributes to the formation and the maintenance of these organs 
[172-174], which makes it difficult to discriminate a clear contribution of RelA. 
Induction of the classical p50/RelA NF-κB activity contributes, but rather involves in 
later developmental stages, such as proper cellular and structural organization of B-cell 
follicles. The phenotypes with respect to secondary lymphoid organogenesis in mice 
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lacking individual Rel/NF-κB family members, upstream kinases, and receptors are 
illustrated in detail in Table 1-4.   
 
LTβR activates both NF-κB signaling pathways in mouse fibroblasts in vitro. It is still 
unclear that which NF-κB activity contributes to which part of secondary lymphoid 
organogenesis. There is also no direct proof that whether RelB and/or RelA does function 
downstream of LTβR signaling in vivo, regulating the development of secondary 
lymphoid organs. It is difficult to draw a conclusion that all lymphoid organ 
developmental defects in mice lack of RelB or RelA are due to the impaired LTβR 
signaling since other receptors are involved in this process as well. Thus, it would be very 
interesting to specifically dissect the individual contribution of each NF-κB pathway 
downstream of LTβR signaling in vivo. Towards this goal, one approach is to generate 
mouse modes in which LTβR-mediated activation of RelB and/or RelA can be selectively 
inactivated (see Figure 3.20). Therefore, relBflox/flox and relAflox/flox mice need to be 
generated and further crossed with transgenic mice expressing Cre recombinase under the 
control of the ltbr promoter (ltbr-cretg mice). Since relBflox/flox mice and ltbr-cretg mice are 
currently not available, the focus of this project is to generate these two mouse lines.  
 
4.2.1  Generation relBflox/flox mice 
A strategy for generating a spatially conditional mutation is to modify the target gene by 
homologous recombination in ES cells so that it can be flanked by the loxP sites. Mice 
containing such a modified gene (floxed mice) are then crossed with mice expressing Cre 
in the desired target tissue, and Cre-mediated excision results in tissue-specific gene 
ablation (see Figure 1.11). 
 
4.2.1.1  Targeting efficiency 
To generate relBflox/flox mice, two targeting vectors were constructed in this study. No 
homologous recombination ES cell clone was found after transfection of the targeting 
vector pRelBXS11.2-LLTNL. This construct constitutes a 4 kb LTNL cassette containing 
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combined pattern of the neo and the HSVtk gene. The advantage of this vector is that a 
negative selection can be performed using ganciclovir to enrich the frequency of floxed 
ES cell clones after transient Cre transfection into homologously recombined ES clones. 
However, only positive selection using G418 is able to be performed after transfecting 
the targeting vector into wild-type ES cells due to the presence of the HSVtk gene in the 
homologously recombined alleles. There are two major factors principally, which can 
influence the targeting frequency. First, the choice of a vector can significantly affect the 
targeting frequency. Secondly, the homologous sequences in the vector, specifically the 
length and the degree of polymorphic variation between the vector and the chromosome. 
The homologous sequences of the targeting vector were confirmed by sequencing, 
excluding the possibility of large mutations during PCR amplification. In order to 
increase the targeting frequency, a second targeting vector was generated based on a 5.84 
kb pTVFlox-0 plasmid. This plasmid constitutes the separate selection marker genes the 
neo gene flanked by two loxP sites and the HSVtk gene (Figure 3.24 A, panel 1)). Using 
this plasmid as the backbone of the targeting vector allows a positive-negative double 
selection. The positive selection marker gene, neo, is primarily used to enrich for the rare 
stably transfected ES cell clones, obtain at a frequency of about one in 104 cells by 
electroporation. The enrichment by negative selection is usually in the range of 3–10-fold 
resulting in 1/10-1/40 of the homologous recombination ES clones as compared to 
random integrants. The positive ES cell clones, combined homologously with the 
targeting vector pTVFlox-LRelBXS11.2, were found and followed the transient Cre 
transfection. The ES cells identified carrying relBflox/+ alleles were injected into 
blastocysts. More than 20 chimeras with different degree of chimerism were generated; 
unfortunately, none of them transmitted to germline. 
 
4.2.1.2  Germ-line transmission 
E14.1 ES cells are derived form 129/Ola mouse strain. E14.1 ES cells (from Prof. Wang 
Z-Q, Lyon, France) exhibited a good record of germline transmission (100% of chimeric 
males) in a test breeding, which confirmed the presence of a certain fraction of germline 
competent cells within the injected ES cells. However, when E14.1 ES cells were 
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transfected, none of the targeted ES cells contributed to germline. Half ES clones (20 
clones injected) gave rise to a satisfactory degree of coat-color chimerism, though. The 
exact reason for the discrepancy is not clear. Using 129/Ola mouse-derived Knut I ES 
cell line (from Dr. Hubert Schorle, Bohn) which is established recently, the gene 
targeting experiment towards generating relBflox/flox mice is ongoing. 
  
4.2.2  Generation of ltbr-cretg mice by pronucleus injection 
To specifically delete RelB or RelA in LTβR-expressing cells, it is necessary to generate 
transgenic mice that express the Cre recombinase under the control of LTβR regulatory 
elements.  
Four independent founder lines, in which Cre expression was driven by a 1.25 kb 
fragment of the mouse LTβR promoter, were generated by pronucleus injection. The 
tissue distribution of cre expression, which was driven by the ltbr promoter, was 
analyzed in offspring from individual founder lines by real-time PCR. Two founder lines, 
in which the cre expression pattern largely reflected the endogenous ltbr expression 
pattern, were further crossed with a reporter mouse line (R26R) for the specific 
characterization. Crossing R26R mice with ltbr-cre transgenic mice allows monitoring 
the Cre expression pattern by lacZ staining. Thus, the expression pattern of lacZ indicated 
the ltbr promoter activity and further reflected the ltbr expression pattern. Mice with 
reliable and faithful tissue specificity will be established as a transgenic line. A wide 
range of tissues from different ltbr-cretg/R26R transgenic line was collected for future 
analysis. The generation of ltbr-cretg mice will be very helpful to characterize the LTβR-
positive cell types, which are not well defined currently in developing and adult mice. 
  
To avoid position and copy number effects influencing the expression pattern of ltbr-cre 
transgenic mice, alternatively, a knock-in mouse line, in which the LTβR coding region 
can be replaced by a Cre cDNA via homologous recombination, is to be generated. The 
corresponding targeting vector pTVFlox-LTβR-Cre was constructed (see Figure 3.29) 
and will be transfected into ES cells in the near future. 
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Once relBflox/flox mice are generated, they will be bred with ltbr-cretg mice to get relBltbr-cre 
mice. The phenotypes in relBltbr-cre and relAltbr-cre mice will then be compared in terms of 
secondary lymphoid organogenesis. With this mouse model system, the distinct role of 
classical (RelA complex) and alternative (RelB complex) NF-κB activation pathway 
downstream of LTβR signaling in lymphoid organogenesis can be characterized in vivo. 
This will broaden our current understanding of NF-κB function in secondary lymphoid 
organ development. The relBflox/flox mice can also be crossed with individual Cre 
transgenic mice controlled by different promoters, for example, CD19-Cre, lck-Cre, 
LysM-Cre [175], K5/K14-Cre, Colalpha1(I)-Cre or OG2-Cre [176], CD11b-Cre [177], 
and Ctsk-Cre mice [178], to dissect the particular function of RelB in B cells, T cells, 
myeloid cells, keratinocytes, osteoblasts, and osteoclasts without the influence of losing 
RelB function in other cell types. Analyzing mice with tissue-specific inactivation of 
RelB will be helpful to understand the severe and complex phenotype of relB-/- mice. 
 
4.3  Outlook  
The future work is focus on: 
1.  To unravel the molecular mechanism by which the elevated RelB activity represses 
the expression of Pax5 and EBF, switching off the B-lineage differentiation program, 
meanwhile, induces the expression of C/EBPα in B-cell progenitors, switching on the 
reprogramming machinery of p100-/- pro-B cells. 
2. To investigate that whether p100 processing, leading to the constitutive p52/RelB 
nuclear translocation, is a downstream event of IL-7R signaling in B-cell precursors. 
3.  To complete the generation of relBflox/flox mice, which will be further crossed with ltbr-
cretg mice. The phenotype analysis in relBltbr-cre and relAltbr-cre mice will be helpful to 
understand the distinct role of classical and alternative NF-κB activation pathway 
downstream of LTβR signaling with respect to lymphoid organogenesis in vivo. 
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